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ABSTRACT 
MATTHEW JAMES COOPER: Kinome Profiling of Drug-Resistant Myeloid Leukemia 
to Guide the Use of Targeted Therapy 
(Under the direction of Dr. Albert S. Baldwin) 
 
 
Protein kinases are key mediators of cellular signaling. Consequently, 
dysregulated kinases are central to cancer initiation, progression and acquired drug 
resistance, and are a major focus in the development of targeted cancer therapies. IKKα, 
is often involved in oncogenic initiation and progression through its role in activating the 
transcription factor NF-κB. However, depending on the context it may function as a 
tumor suppressor. This concept has been demonstrated here. Chapter 2 discusses work 
exploring the functional relationship between IKKα and the androgen receptor (AR) in 
prostate cancer cells. It is shown that IKKα and AR physically interact, that IKKα 
overexpression attenuates AR activity and that, conversely, IKKα ablation results in 
increased AR activity. IKKα phosphorylates AR at Ser29, and mutation of this site causes 
AR to be refractory to IKKα inhibition. These results indicate a previously unreported 
role for IKKα as a tumor suppressor in prostate cancer. Chapter 3 discusses work using 
novel multiplexed kinase inhibitor beads (MIBs) coupled with quantitative mass 
spectrometry (MS) to compare the kinase expression and activity of a Lyn-driven 
imatinib-resistant cell line, MYL-R, and its imatinib-sensitive counterpart, MYL. 
Expression and activity changes of 153 kinases were measured from various protein 
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kinase families, and statistical analysis identified 35 kinases with significant differences, 
referred to as the MYL-R kinome profile. MIB/MS and immunoblot analysis confirmed 
the over-expression and activation of Lyn in MYL-R cells and identified additional 
kinases with increased (e.g., MEK, ERK, IKK, PKCβ, NEK9) or decreased (e.g., Abl, 
Kit, JNK, ATM, Yes) abundance or activity. Pharmacological and shRNA-mediated Lyn 
inhibition reduced MEK and IKK phosphorylation. MYL-R cells showed elevated NF-
κB signaling relative to MYL cells, so the effects of the IKK inhibitor, BAY 65-1942 
(BAY), were tested. Further MIB/MS analysis revealed that BAY increased MEK/ERK 
signaling, which was prevented by co-treatment with a MEK inhibitor (AZD6244). The 
combined inhibition of IKKα and MEK resulted in synergistic loss of cell viability, 
leading to apoptosis. These results demonstrate the utility of MIB/MS as a tool to identify 
dysregulated kinases and to interrogate kinome dynamics as cells respond to targeted 
kinase inhibition. 
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 CHAPTER I 
KINASE SIGNALING IN CANCER 
1.1 Dysregulated kinases and oncogenic signaling 
The human kinome consists of the approximately 518 members of the protein 
kinase super family and represents one of the largest gene families, constituting nearly 
2% of the genome [1]. Protein kinases are key mediators of cellular signaling, regulating 
such processes as metabolism, gene transcription, cell cycle regulation, cell motility, 
differentiation and apoptosis. Consequently, dysregulated kinases play key roles in 
oncogenic signaling, cancer progression and acquired drug resistance, and are a major 
focus in the development of targeted cancer therapies. 
Src kinase was the first discovered oncogene (as well as the first discovered 
tyrosine kinase), gaining this distinction when it was identified as the cell-transforming 
factor of the Rous sarcoma virus [2,3]. Many other kinases have been identified as proto-
oncogenes since then, demonstrating the capacity for oncogenic signaling once they are 
dysregulated through a variety of mechanisms including activating mutations, protein 
overexpression, excessive stimulation or loss of feedback inhibition [4–6]. Following are 
just a few examples of such kinases dysregulated in cancer. 
The BCR-Abl tyrosine kinase is the constitutively active product of the reciprocal 
translocation between chromosomes 9 and 22, and is the causative oncoprotein in over 
95% of chronic myeloid leukemia (CML) [7]. The receptor tyrosine kinases (RTKs) 
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FLT3 and c-Kit are growth factor receptors essential for normal hematopoietic 
development, but which have activating mutations or are overexpressed in a majority of 
acute myeloid leukemia cases (AML) [8–10]. EGFR and Her2 are growth factor RTKs 
overexpressed or mutated in various epithelial malignancies including lung and colorectal 
cancers (EGFR) [11] and breast cancer (Her2) [12]. The JAK tyrosine kinases transmit 
signals from RTKs via the STAT transcription factors, but through activating mutations 
or excessive RTK activity they may contribute to myeloproliferative neoplasms and 
leukemia [13,14]. Finally, the IKK serine/threonine kinases transmit signals from various 
cell receptors and MAP3Ks to activate the NF-κB transcription factor family; however 
constitutive activation of IKK by overexpression or aberrant upstream signaling is a 
contributing factor in many different cancers [15]. 
In addition to kinase dysregulation caused by mutation or overexpression, 
aberrant kinase activation may result from excessive stimulation or loss of feedback 
inhibition. Cytokine overproduction, for example, will lead to increased activity of 
cognate receptors (e.g., RTKs), increasing the activity of downstream effector kinases 
(e.g., JAKs and MAPK) [16]. Similarly, mutation or overexpression of adaptors or other 
proteins involved in signal transduction (e.g., Grb2 and SOS, or Ras) will lead to 
increased activity of effector kinases [17]. Conversely, excessive kinase activity may be 
the result of lost inhibitory regulation by other proteins. Loss of the phosphatase PTEN, 
for example, results in lost Akt inhibition and is causal in numerous cancers [18]. 
Disruption of ERK-dependent feedback inhibition of Raf, as observed in the B-Raf 
(V600E) mutation, leads to enhanced activity of the Raf/MEK/ERK pathway [19]. 
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1.2 IKK dysregulation in cancer 
The IκB Kinases (IKK) represent a major convergence of cell growth and survival 
signaling and as a result are commonly involved in the initiation, progression and drug 
resistance of numerous malignancies. Stimuli known to activate IKK include: growth 
factors, oxidative stress, UV irradiation, and bacterial and viral infection [15,20]. IKKα 
and IKKβ are highly similar serine/threonine kinases that typically participate in one of 
two distinct signaling complexes distinguished by the presence or absence of the NEMO 
regulatory subunit (also known as IKKγ). In association with NEMO, IKKα/IKKβ 
heterodimers form a high molecular weight holoenzyme referred to as the IKK complex 
which activates the canonical NF-κB pathway [21,22]. Depending on the activating 
stimuli, an IKKα homodimer may substitute for the IKKα/IKKβ heterodimer in this 
NEMO-dependent complex [23,24]. IKKα homodimers also form a NEMO-independent 
complex to activate NF-κB through an alternative pathway [25,26]. 
NF-κB regulates a plethora of genes involved in inflammation, innate and 
adaptive immunity, survival and proliferation. The NF-κB family is comprised of five 
subunits (p65 (or RelA), RelB, c-Rel, p100/p52, and p105/p50) each containing a 
conserved amino-terminal Rel homology domain which confers the ability to form 
hetero- and homodimers, bind consensus κB DNA elements, and interact with the 
Inhibitor of κB (IκB) proteins [27]. In unstimulated cells NF-κB interacts with IκB, 
which contains a nuclear export signal and masks the nuclear localization signal of NF-
κB to retain the complex in the cytoplasm [28,29]. In the canonical NF-κB activation 
pathway, pro-inflammatory cytokines (e.g., TNFα and IL-1) and toll-like receptor 
agonists (e.g., LPS) are among stimuli that lead to activation of the IKK complex through 
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TAK1 (MAP3K7). IKK phosphorylates the IκB proteins associated with NF-κB (e.g., 
p65/p50), marking them for degradation and liberating NF-κB to translocate to the 
nucleus [15,30]. In the alternative NF-κB pathway, TNF family ligands such as CD40L, 
LTβ and RANKL lead to activation of IKKα homodimers through NIK (MAP3K14). 
IKKα in turn phosphorylates NF-κB p100 and marks it for processing into p52, thereby 
activating the NF-κB RelB/p52 heterodimer [31]. 
On account of their central role in cell survival and proliferation, constitutive 
activation of NF-κB and IKK is observed in many cancers [15,20,32]. Precise regulation 
is therefore critical, and is the object of various negative feedback mechanisms. One of 
the earliest transcriptional targets of NF-κB is its own inhibitor, IκBα. Newly synthesized 
IκBα serves to retrieve active NF-κB from the nucleus by masking the NF-κB nuclear 
localization sequence [27]. This feedback mechanism is critical for regulating the 
duration of the NF-κB response, and loss of IκBα is associated with constitutive 
activation of NF-κB in tumor cells [32]. Another transcriptional target of NF-κB includes 
the deubiquitinating enzyme A20, which joins the tumor suppressor CYLD to regulate 
aspects of IKK activation. Upon stimulation of TNF receptor family members, receptor-
associated factors (e.g., TRAF6, RIP1, IRAK1) undergo K63-linked polyubiquitination 
which facilitates recruitment of IKK and the TAK1 complex resulting in IKK activation. 
CYLD and A20 serve to deubiquitinate these factors in order to attenuate activation of 
IKK, and inactivating mutation of these tumor suppressor proteins leads to oncogenic 
transformation [33]. 
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1.3 Cross-talk in IKK activation  
In addition to signaling transduced by cytokine and toll-like receptors, IKK 
receives input through cross-talk from other signaling pathways [34]. For example, NF-
κB can be activated by signaling from epidermal growth factor receptors (EGFR) or 
oncogenic Ras. The EGFR family member Her2, which is amplified in 30% of breast 
cancers, has been shown to activate the canonical NF-κB pathway through IKKα [35]. 
Oncogenic Ras, found in 30% of all tumors, has been shown to mediate lung epithelial 
cell transformation through canonical NF-κB with a requirement for IKKβ [36,37]. 
Following are a few brief examples of kinases involved in other signaling pathways that 
have been reported to activate IKK. 
Elements of the MAPK pathway, including MEKK1, have been shown to activate 
IKK [38]. For example, IKK is phosphorylated by a MEK/ERK/RSK cascade initiated by 
either ATM or DNA-PK in response to DNA damage induced by topoisomerase 
inhibitors [39]. Finally, Akt has been shown to activate IKK, both directly through 
phosphorylation or indirectly through activation of other kinases such as Tpl-2/Cot 
(MAP3K8) or mTOR [40–42]. 
1.4 NF-κB-independent actions of IKK 
IKKα and IKKβ were first isolated from TNFα-induced HeLa cell extracts based 
on their IκB kinase activity [21]. However, NF-κB-independent functions for each have 
been demonstrated since [34]. Nevertheless, the NF-κB-independent actions of IKKβ 
generally complement NF-κB in that they inhibit tumor suppressor function while 
supporting pro-inflammatory signaling. For example, IKKβ was shown to phosphorylate 
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and induce degradation of the tumor suppressor FOXO3a, increasing proliferation and 
tumorigenesis of breast cancer cells [43]. IKKβ was also shown to phosphorylate and 
destabilize the tumor suppressor TSC1, thereby relieving inhibition of mTOR [44]. 
Finally, IKKβ was shown to regulate LPS-stimulation of the MAPK pathway by 
phosphorylating NF-κB p105 in complex with Tpl-2, thus dissociating the complex and 
allowing Tpl-2 to activate MEK [45,46]. 
In contrast to IKKβ, IKKα plays a diverse role in cell signaling by supporting 
either pro- or anti-proliferative activities. IKKα can promote cell proliferation by 
enhancing gene transcription through effects on chromatin. First, IKKα can 
phosphorylate the SMRT repressor complex and lead to derepression of promoters, thus 
allowing the recruitment of coactivators [47]. Second, it can phosphorylate the steroid 
receptor coactivator 3 (SRC-3) to increase its nuclear localization and enhance 
transcription [48]. Finally, IKKα can be recruited to promoters with CREB-binding 
protein (CBP) where it phosphorylates histone H3 Ser10, allowing the acetylation of 
Lys14 to recruit transcriptional coactivators [49,50]. 
The transcription of non-NF-κB-mediated genes has also been shown to be 
promoted by a sequence of these IKKα actions. In response to estrogen stimulation IKKα 
phosphorylates estrogen receptor α (ERα) at serine 118, a mark associated with enhanced 
ER-mediated gene transcription, and also phosphorylates SRC-3. IKKα then co-localizes 
to promoters with the ERα/SRC-3 complex where it phosphorylates histone H3 Ser10 
[51]. 
Diverging roles for IKKα can be illustrated by its varying effects on cyclin D1 
protein levels. IKKα has been shown to phosphorylate and stabilize β-catenin thereby 
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promoting transcription of TCF/LEF target genes, including the oncogene cyclin D1 
[52,53]. Conversely, IKKα has also been shown to directly phosphorylate cyclin D1, 
leading to its nuclear export and degradation. Furthermore, IKKα-/- MEFs showed 
increased cyclin D1 expression predominantly localized to the nucleus and are 
tumorigenic when injected into nude mice, a phenotype that was rescued by 
reconstitution of IKKα. This latter effect on cyclin D1 points to a possible tumor 
suppressor role for IKKα [54,55]. 
Further evidence of a tumor suppressor role for IKKα has been shown in studies 
involving the formation of squamous cell carcinoma (SCC) in keratinocytes. Low IKKα 
expression was observed in a large number of poorly differentiated SCC samples [56]. It 
was later shown that reconstitution of IKKα in knockout mice reduced the formation of 
SCC and induced terminal differentiation of keratinocytes through the TGFβ-SMAD 
pathway [57]. Further studies showed that while ectopic expression of IKKβ induced 
chronic inflammation in mouse epidermis, IKKα had no such effect but led to the 
upregulation of c-myc antagonists and suppressed an EGFR-Ras-ERK-EGFR ligand 
autocrine loop that promoted keratinocyte differentiation [58]. 
1.5 Kinase signaling to androgen receptor in prostate cancer 
Prostate cancer (PCa) is the most frequently diagnosed cancer and is the second 
leading cause of cancer deaths among men, claiming nearly 30,000 lives each year [59]. 
Development and maintenance of the prostate is dependent on androgens, which activate 
the AR to control expression of genes involved in growth, proliferation and 
differentiation of prostate cells. 
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Newly synthesized AR is located in the cytoplasm, bound to a multi-protein 
chaperone complex. Following ligand binding, AR undergoes conformational 
changes[60], dissociates from its chaperone complex and is phosphorylated, protecting it 
from degradation and stabilizing homodimer formation [61]. Ligand-bound AR 
translocates to the nucleus, binds androgen response elements (AREs) upstream of target 
genes and either represses or transactivates genes, depending on the recruitment of 
coregulators [62]. The ability of AR to recruit coactivators or corepressors is influenced 
by their relative abundance and by additional AR phosphorylation. Mutations in AR 
(ligand binding domain and gene amplification) and aberrant signaling or 
phosphorylation may lead to androgen independence and oncogenesis through altered 
function or through activation in the absence of appropriate ligand [60,63–65]. 
Several phosphorylation sites have been identified on AR, but the majority have 
no established function. Among the serine/threonine kinases confirmed to phosphorylate 
AR are CDK1, CDK7, Akt, Aurora-A, MEK, PKC, JNK and p38. These kinases have 
been shown to phosphorylate AR under basal conditions or in response to androgen, 
epidermal growth factor (EGF), insulin-like growth factor (IGF) or serum. Akt has been 
shown to phosphorylate AR on Ser213 and Ser791 in response to EGF and IGF, however 
conflicting reports have emerged on the effect that these events have on AR function. 
Phosphorylation of AR by Aurora-A, MEK, and PKC is androgen-independent (MEK 
and PKC being induced by EGF) and mutations of these sites reduce activity of AR 
measured by in vitro reporter assays. Finally, JNK and p38 phosphorylate AR Ser650 
which has been shown to induce AR nuclear export and antagonizes AR transcriptional 
activity [66,67]. 
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AR is also phosphorylated by tyrosine kinases and although these sites are fewer 
in number more have established functions. EGF induces tyrosine phosphorylation by Src 
at Tyr534, and by Ack at Tyr267 and Tyr363. In addition to EGF, IL-6 and Bombesin 
induce Src-dependent phosphorylation while Heregulin and Gas6 induce Ack-dependent 
phosphorylation. Studies have shown that these modifications increase AR transcriptional 
activity and drive tumor growth [68,69]. 
The numerous reports of NF-κB-independent functions for IKKα, together with 
its demonstrated signaling diversity, raise the possibility of many yet undiscovered roles 
for IKKα in various aspects of cell signaling [47,49,50]. Given the activities of IKKα in 
promoting ERα-mediated gene transcription [51], we hypothesized that IKKα might play 
an analogous role in promoting androgen receptor (AR) activity. Chapter 2 of this 
dissertation discusses studies aimed at elucidating a functional interaction between IKKα 
and AR in prostate cancer cells. Therein I report the novel finding that IKKα and AR 
associate and that IKKα phosphorylates and attenuates AR activity, consistent with a 
tumor suppressor role for IKKα. 
1.6 Kinase signaling in leukemia 
Leukemia is a clonal disorder of hematopoietic stem cells characterized by an 
accumulation of undifferentiated blood cells, or blasts. It is broadly grouped as myeloid 
or lymphoid according to which lineage the blasts have descended from, and is further 
classified as acute or chronic depending on the extent of differentiation and rate of 
proliferation of the blasts [70]. As a group, leukemia is the most common cancer in 
children aged 0 to 14 years. It accounts for only 3% of newly diagnosed cancers in both 
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men and women (approximately 48,600 new cases per year), however the estimated 5-
year survival rate is approximately 50%. Moreover, leukemia is the leading cause of 
cancer death among males under age 40 years and among females under age 20 years 
[71]. 
Acute myeloid leukemia (AML) is characterized by rapid growth and 
accumulation of undifferentiated myeloid blasts. It is a very heterogeneous disease both 
biologically and clinically, with 55% of cases exhibiting cytogenetic defects that result in 
numerous fusion proteins (e.g., RUNX1/ETO and PML/RARα), mutated transcription 
factors (e.g., CEBPα and RUNX1) and mutated epigenetic modifiers (e.g., DNMT3A and 
EZH2) [72–74]. Commonly upregulated signaling molecules include Ras and the 
receptor tyrosine kinases c-Kit and FLT3, the latter being found in 30% of AML cases 
[8,9,75]. 
AML is one of the most difficult leukemias to treat and is characterized by a high 
rate of relapse, drug resistance and mortality.  Despite decades of research, there has been 
little improvement in the treatment of this disease [76]. It is estimated that there will be 
approximately 15,000 new cases of AML diagnosed in the U.S. this year and it will be 
attributed to over 10,000 deaths [59]. Relapse of AML after initial complete remission is 
very common. The 5-year relative survival rate is below 50% in patients younger than 60 
years and below 10% in patients older than 60 years. Clinical trials involving inhibitors 
of FLT3, the most common mutation in AML have largely failed [77–79]. Treatment 
options for relapsed or refractory disease and elder patients are limited mainly to clinical 
trials or stem cell transplant if applicable [73]. Thus the discovery of novel therapies is 
crucial for more durable remissions and the cure of AML. 
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Chronic myeloid leukemia (CML) is characterized by the accumulation of 
incompletely differentiated myeloid blasts. A hallmark of CML is the reciprocal 
translocation between chromosomes 9 and 22, (i.e., the Philadelphia chromosome), which 
is the causative oncogene in over 95% of chronic myeloid leukemia (CML) cases [7]. 
This forms the constitutively active BCR-Abl tyrosine kinase which promotes cytokine-
independent growth and proliferation through downstream pathways such as Ras, Raf, 
JNK and STAT [80]. Imatinib (Gleevec™), a small molecule ATP-competitive inhibitor 
of BCR-Abl, is an effective front-line treatment for CML and has established the concept 
of targeted kinase inhibition as a viable strategy for cancer therapy [81]. However, 
whereas the majority of newly diagnosed CML patients undergo remission, some patients 
are refractory to imatinib therapy and others who initially respond will eventually 
develop imatinib resistance [82–84]. 
Multiple mechanisms of cellular resistance to imatinib have been described and 
include BCR-Abl-dependent mechanisms such as protein overexpression or expression of 
inhibitor-resistant mutations in the BCR-Abl kinase domain, such as the T315I 
“gatekeeper mutation” [85]. This mutation reduces the affinity of tyrosine kinase 
inhibitors while increasing the leukemogenic signaling of BCR-Abl [86–88]. Resistance 
also arises from BCR-Abl-independent mechanisms such as alterations in drug import or 
export that affect intracellular imatinib levels [89–92], clonal evolution as the result of 
additional genetic abnormalities [93,94], and up-regulation of alternative signaling 
pathways [87,95]. 
Compensatory upregulation of kinases such as AKT or Src family kinases (SFKs) 
have been implicated in imatinib resistance whereby these kinases drive alternative cell 
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survival and proliferation signaling [85,96–99]. For instance, hyper-activation of Lyn or 
Hck has been associated with imatinib resistance in CML patients and cell culture models 
[100–103], albeit the mechanisms by which these kinases contribute to imatinib 
resistance are not well understood. Moreover, a recent study reported that SFKs are 
frequently involved in promoting inhibitor-resistant CML, even after successful 
inhibition of BCR-Abl activity [104]. 
Indeed, because of the essential roles that kinases play in cell survival and 
metabolism, there is an inherent ability of kinase networks to adapt and compensate for 
new pressures. Given the dynamic nature of the kinome, single kinase inhibitors often 
have limited success as cancer therapies, demonstrating the need for effective 
combination therapies [85]. This, in turn, demands a strategy to comprehensively survey 
active kinase pathways and to monitor a cell’s response to inhibition of specific kinases. 
1.7 Kinome profiling to guide targeted therapy 
Kinome adaptation studies have typically utilized phospho-specific antibody 
arrays or have relied on immunoblotting of select kinases [105]. However, these studies 
are limited in scope by the available antibodies and are subject to experimental bias. 
Large-scale proteomics studies have analyzed differential protein expression and 
phosphorylation in drug-resistant leukemias using standard proteomics techniques. 
However, these involve methods such as 2D-differential in-gel electrophoresis (2D-
DIGE), which are material- and labor-intensive. Or they rely on immunoprecipitation of 
phospho-tyrosine peptides from complex mixtures, which isolates a large portion of the 
phosphoproteome without preference for kinases [106–109]. Because protein 
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identification by mass spectrometry is an essential downstream step in these proteomics 
studies, a simplified analyte is essential to achieve good protein sequence coverage [110]. 
Obtaining a comprehensive profile of the kinome (which constitutes only 2% of the 
genome) from cell lysates will therefore benefit from kinase enrichment, preferably with 
a bias toward kinase activation state. 
One promising solution is the chemical proteomics approach described by 
Patricelli et al. [111,112]. This method involves the use of ATP/ADP probes linked to 
biotin through an acyl phosphate bond. Active kinases bind the probe, whereupon the 
conserved lysine of the kinase active site cleaves the linker and is covalently modified by 
the biotin moiety. Biotinylated peptides fragments are then isolated and identified by LC-
MS/MS. 
Duncan et al. have recently adapted a chemical proteomics approach used by 
Daub that couples kinase affinity capture with quantitative mass spectrometry  [113,114]. 
In this method, a mixture of broad spectrum kinase inhibitors target the ATP-binding 
pocket and allow the unbiased capture of kinases, based on activity state and abundance. 
Quantitative methods of mass spectrometry (e.g., iTRAQ and SILAC) are subsequently 
applied to evaluate kinome changes on a global scale. 
Chapter 3 of this dissertation discusses the application of multiplexed kinase-
inhibitor-conjugated beads coupled with quantitative mass spectrometry (MIB/MS) to 
investigate kinome adaptations in a cell line model of Lyn-driven, imatinib-resistant 
CML (MYL-R) compared to its imatinib-sensitive counterpart (MYL) [101]. We 
identified multiple changes associated with drug-resistance in MYL-R cells, including 
activation of IKKα and MEK downstream of Lyn signaling. Furthermore, MIB/MS 
14 
analysis of the kinome response to targeted kinase inhibition identified a compensatory 
increase in MEK/ERK signaling when IKKα was inhibited alone. Combined targeted 
inhibition of IKKα and MEK, as guided by MIB/MS, overcame MYL-R drug resistance 
and synergistically inhibited cell viability. 
 CHAPTER II 
FUNCTIONAL INTERACTION OF IKKα AND THE ANDROGEN RECEPTOR 
2.1 Overview 
Prostate cell growth is regulated by the androgen receptor (AR) which is typically 
activated by binding of androgen, leading to the nuclear translocation of AR and 
regulation of a variety of target genes. The strength and specificity of AR signaling is 
determined by binding of androgens, posttranslational modifications and the interaction 
of AR with a number of coregulators. The Ser/Thr protein kinase IKKα associates with 
AR in prostate cancer cell lines and attenuates its activity. Genetic and pharmacological 
inhibition of IKKα results in increased AR protein levels and increased nuclear 
accumulation in response to androgen, with correlating increases in the AR target genes 
KLK2, PSA, FKBP5 and TMPRSS2. Conversely, overexpression of IKKα results in 
reduced AR protein levels and reduced AR target gene expression. IKK in vitro assays 
result in robust phosphorylation of AR and the formation of multiple phospho-protein 
isoforms after resolving by SDS-PAGE. We have mapped IKKα phosphorylation to AR 
serine 29 (S29) by mass spectrometry and have validated this site in situ using a phospho-
serine motif antibody and a phospho-null AR S29A mutant. AR S29 flanks the NH2-
terminal FXXLF motif essential for AR stability and intramolecular interaction and may 
therefore play a role in regulation of AR transcriptional activity. Indeed, S29A confers 
increased protein stability to AR, and results in increased activity in the presence of IKKα 
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as measured by luciferase reporter assay. This novel role for IKKα suggests that in the 
context of prostate cancer, it may serve as a tumor suppressor by inhibiting aberrant AR 
activity. 
2.2 Introduction 
Prostate cancer (PCa) progression is initially driven by the androgen receptor 
(AR), which responds to androgen and regulates genes controlling the growth, 
differentiation and proliferation of prostate epithelial cells. In advanced PCa, however, 
AR gains androgen independence as a result of mutations, excessive protein expression 
or activation by aberrant signaling. Elucidating protein interactions that modulate AR 
behavior is therefore pertinent to our understanding of PCa progression. 
Prostate cancer (PCa) is the most frequently diagnosed cancer and is the second 
leading cause of cancer deaths among men [71]. Development and maintenance of the 
prostate is dependent on androgens, which activate the AR to control expression of genes 
involved in growth, proliferation and differentiation of prostate cells. After 
carcinogenesis, prostate cells remain dependent on AR for growth and survival, making 
androgen ablation an effective therapy for PCa [115]. Advanced PCa, however, gains 
androgen independence as mutations in the AR, excessive AR protein expression, or 
aberrant signaling to AR leads to its activation in the absence of androgen [116–118]. 
Proper control of prostate cell proliferation and maintenance is achieved through 
context-dependent roles for AR in the different prostate compartments. AR is expressed 
in the stromal cells and responds to 5α-dihydrotestosterone (DHT) to regulate expression 
of growth factors (i.e., andromedins), which diffuse into the epithelial compartment to 
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stimulate proliferation of the basal cells while promoting survival of the secretory luminal 
cells. In the epithelial compartment, AR is expressed abundantly in the secretory luminal 
cells and responds to DHT to regulate expression of prostate-specific differentiation 
markers, such as prostate specific antigen (PSA) and kallikrein 2 (KLK2), and to 
suppress proliferation of these cells [119]. Thus, the function of AR is context-dependent, 
its activation resulting in either promotion or suppression of cell proliferation depending 
on the genes regulated [117,120,121].  
The AR is composed of 919 amino acids arranged in four functional domains.  
The N-terminal domain (NTD) consists of amino acids 1-558; it contains the activation 
function (AF) 1 region, which contains the primary transactivation activity of the AR, 
and has an FXXLF motif that is critical for interaction with the C-terminus. This N/C 
interaction occurs after androgen binding and positively effects the duration of AR ligand 
binding and stability [122]. The DNA-binding domain (DBD) consists of amino acids 
559-624 and is essential for binding to androgen response elements (AREs) of target gene 
enhancers and promoters. A hinge region stretches between the DBD and the ligand-
binding domain (LBD) and contains a nuclear localization signal (NLS). The LBD 
consists of amino acids 676-919 and contains the AF-2 domain which, after binding 
ligand, forms a hydrophobic cleft that serves as a docking site for coactivators which 
compete with the FXXLF motif for binding [60,123–125]. 
Newly synthesized AR is located in the cytoplasm, bound to a multi-protein 
chaperone complex. Following ligand binding, AR undergoes conformational 
changes[60], dissociates from its chaperone complex and is phosphorylated, protecting it 
from degradation and stabilizing homodimer formation [61]. Ligand-bound AR 
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translocates to the nucleus, binds androgen response elements (AREs) upstream of target 
genes and either represses or transactivates genes, depending on the recruitment of 
coregulators [62]. The ability of AR to recruit coactivators or corepressors is influenced 
by their relative abundance and by additional AR phosphorylation. Mutations in AR 
(ligand binding domain and gene amplification) and aberrant signaling lead to androgen 
independence through altered function or through activation in the absence of appropriate 
ligand [60,63–65]. 
IKKα is a Ser/Thr protein kinase that associates with the IKK complex to induce 
the transcription factor NF-κB [15]. Independent of its role in the NF-κB pathway, IKKα 
activates a variety of genes through histone phosphorylation and recruitment of proteins 
associated with active transcription, such as CBP and SRC-3 [49,50,126]. Tumor 
suppressor roles have been described for IKKα in squamous cell carcinoma, where it is 
essential to maintaining keratinocyte differentiation [57,127]. 
Based on the role that IKKα plays in promoting gene transcription [47,49,50] and 
a report that estrogen receptor requires IKKα for functionality [51], we asked whether 
IKKα might play a role in AR function. These studies used the androgen-sensitive 
LNCaP cell line, a commonly studied PTEN-null prostate carcinoma (PCa) cell line that 
expresses AR. 
Knockdown or pharmacological inhibition of IKKα resulted in increased AR 
receptor activity, demonstrated by increased expression of AR target genes KLK2, PSA, 
FKBP5 and TMPRSS2. Conversely, overexpression of IKKα resulted in a dose-
dependent decrease in ARE-responsive luciferase reporter activity. IKKα inhibition also 
led to increased AR protein levels and increased nuclear accumulation of AR in response 
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to androgen treatment. Co-immunoprecipitation studies demonstrated that IKKα and AR 
physically interact in different PCa cells lines and when exogenously expressed in HEK 
293T cells. In addition, AR was strongly phosphorylated by IKKα in vitro. We used mass 
spectrometry to map the IKKα phosphorylation site to AR S29 and used a phospho-null 
mutant and phospho-serine motif antibody to demonstrate phosphorylation of S29 in situ 
in conjunction with IKKα reconstitution or overexpression. Finally, we observed that AR 
S29A had increased stability and luciferase reporter activity in the presence of IKKα 
compared to AR WT. Thus, we conclude that IKKα inhibits AR activity via 
phosphorylation of S29 and in this context acts as a tumor suppressor. 
2.3 Results and Discussion 
IKK attenuates Androgen Receptor activity 
To assess the effect of IKK on androgen receptor (AR) activity, IKKα and IKKβ 
were transiently knocked down in the LNCaP prostate cancer cell line and the relative 
expression of AR target genes was measured using quantitative PCR (qRT-PCR). LNCaP 
cells were transfected with siRNA (20 nM) directed against IKKα and IKKβ, or with 
non-targeting control siRNA. 72 hours post-transfection, the cell growth medium was 
replaced with medium containing steroid-depleted serum (charcoal-dextran-stripped fetal 
bovine serum, CDS-FBS) and cells were grown for an additional 24 hours to deplete cells 
of steroid. Cells were treated with 5α-dihydrotestosterone (DHT; 10 nM) or ethanol 
vehicle control to induce AR activity and after 24 hours cells were harvested for isolation 
of total RNA and qRT-PCR analysis. As shown in Figure 2.1A, siRNA-mediated 
knockdown of IKKα and IKKβ resulted in increased basal and DHT-induced expression 
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of AR target genes KLK2, PSA and FKBP5. This effect may have been caused by a 
direct interaction of IKKα/IKKβ with AR, or by sustained knockdown of IKKα/IKKβ 
decreasing NF-κB activity and relieving its inhibitory cross-talk with the AR pathway 
[128,129]. 
To investigate the effects of short-term IKK inhibition on AR activity, we treated 
LNCaP cells with the small molecule IKK inhibitor, BAY 65-1942 (BAY) [130] at 
concentrations sufficient to inhibit IKKα and IKKβ (5 μM and 1 μM, respectively) [131]. 
Androgen-depleted cells were treated for 2 hours with BAY (1 μM or 5 μM) prior to 
stimulation for 8 hours with DHT (10 nM), cells were harvested for isolation of RNA and 
qRT-PCR analysis of AR target gene expression (Figure 2.1B). Treating cells with 1 μM 
BAY did not significantly affect basal or DHT-induced gene expression. However, 
treating cells with 5 μM BAY resulted in a moderate increase in basal and DHT-induced 
gene expression compared to DMSO treated cells. 
Overexpressing IKK in LNCaP cells resulted in reduced expression of ARR2PB-
luciferase reporter in a dose-dependent manner. LNCaP cells depleted of steroid were 
transfected with the AR-responsive ARR2PB-luciferase reporter vector and with empty 
vector or increasing amounts of IKKα or IKKβ. After 24 hours cells were treated with 
DHT (0.1 nM or 10 nM) or ethanol vehicle for an additional 24 hours and were harvested 
for luciferase assay. Expression of IKKα and IKKβ reduced luciferase reporter activity 
(Figure 2.1C), with IKKα having a more pronounced dose-dependent effect. Co-
expression of increasing amounts of IKKα or IKKβ decreased basal luciferase reporter 
activity by ≈ 74-83% and ≈ 55-68%, respectively. Luciferase reporter activity induced by 
low (0.1 nM) DHT was reduced by increasing amounts of IKKα or IKKβ by ≈ 84-97% 
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and ≈ 56-74%, respectively. Luciferase reporter activity induced by high (10 nM) DHT 
was reduced by increasing amounts of IKKα or IKKβ by ≈ 68-95% and ≈ 13-49%, 
respectively. ARR2PB-luciferase reporter activity was more sensitive to expression of 
IKKα and was less sensitive to expression of IKKβ, especially at high (10 nM) DHT. 
IKKα reduced luciferase activity at 0, 0.1 nM and 10 nM DHT in a dose-
dependent manner. IKKβ had somewhat less of an effect on AR activity, especially in 
cells stimulated with 10 nM DHT. The effects of IKKα on AR activity may be mediated 
through direct effects on AR. Knocking down IKKα in LNCaP cells involved culturing 
cells in steroid-depleted medium for 72 hours; during this time AR levels were reduced 
likely because there was no androgen present to stabilize AR protein [122]. However, 
IKKα knockdown resulted in increased AR protein levels (Figure 2.1D). There was no 
effect on AR mRNA levels, indicating that IKKα may mediate AR protein stability, 
thereby modulating its activity. 
Sustained IKKα depletion increases AR activity and is rescued by IKKα overexpression 
To characterize the effects of IKKα on AR activity we transduced LNCaP cells 
with control shRNA or shRNA targeting IKKα and established stable cell lines 
designated LNCaP-shC (control cells) and LNCaP-shIKK, respectively. As observed 
with transient IKKα knockdown, stable knockdown resulted in increased AR protein 
expression (Figure 2.2A) further suggesting protein stability as a mechanism by which 
IKKα modulates AR activity. 
In order to verify the effects of IKKα knockdown on AR target gene expression, 
LNCaP-shIKK were grown in CDS-FBS medium for 24 hours prior to stimulation for 8 
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hours with DHT (10 nM), total RNA was isolated and gene expression was analyzed by 
qRT-PCR as before. In support of our previous observations (Figure 2.1A), stable 
knockdown of IKKα in LNCaP cells resulted in increased expression of AR target genes 
(Figure 2.2B). Basal expression of KLK2 was increased significantly (≈ 2-fold) in 
LNCaP-shIKK compared to the control LNCaP-shC cell line, while basal expression of 
PSA and TMPRSS2 were only modestly increased. However, DHT-induced expression 
of both KLK2 and PSA was increased ≈ 2-fold in LNCaP-shIKK compared to the control 
cells. 
Sustained depletion of IKKα resulted in increased AR activity as measured by 
changes in target gene expression. In order to confirm the role of IKKα we attempted to 
rescue the knockdown phenotype by co-transfecting LNCaP-shIKK and control cells with 
an AR-responsive ARR2PB-luciferase reporter and a vector expressing IKKα. Cells were 
grown in CDS-FBS medium for 24 hours prior to transfection and upon transfection were 
treated with DHT (10 nM) or ethanol vehicle control for an additional 24 hours before 
being harvested for luciferase assay. As shown in Figure 2.2C, both basal and DHT-
induced luciferase activity is significantly higher in LNCaP-shIKK compared to control 
cells, and luciferase activity is effectively blunted by reconstituting cells with IKKα. 
These observations show that IKKα, and to a lesser extent IKKβ, attenuated AR 
activity in the LNCaP prostate cancer cell line. Depletion of IKKα resulted in increased 
expression of AR protein, and consequently led to increased expression of AR target 
genes or AR-responsive luciferase reporters. Furthermore, the IKKα knockdown 
phenotype was rescued by ectopic expression of IKKα. These results indicate that IKKα 
functions as a negative regulator of AR activity in the LNCaP prostate cancer cell line. 
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IKKα associates with AR in prostate cancer cell lines 
IKKα participates in NF-κB-dependent and -independent signaling and may affect 
AR activity through a variety of mechanisms [47,49–51]. In order to investigate the 
possibility that IKKα directly affects AR activity we sought to establish whether IKKα 
and AR physically interact. Prostate cancer cell lines LNCaP and VCaP were cultured for 
24 hours in CDS-FBS growth medium to deplete cells of steroids and were stimulated for 
1 hour with DHT (10 nM). IKKα, IKKβ and AR (Figure 2.3A, B) were 
immunoprecipitated from cell lysate, and eluates were separated by SDS-PAGE and 
analyzed by immunoblot. As shown in Figure 2.3A, IKKα and AR co-
immunoprecipitated from LNCaP and VCaP cell lysates under basal conditions and with 
1 hour treatment with DHT. The IKK-AR association was not significantly altered by the 
presence of androgen, however treatment with higher levels of DHT (10 nM) led to a 
slight loss of AR co-immunoprecipitated with IKKα (Figure 2.3A, left panel). AR also 
co-immunoprecipitated with IKKβ in LNCaP cells (Figure 2.3B), however this 
association appeared to be more transient and was only observed after multiple attempts 
with different lysis and immunoprecipitation conditions. The ability of exogenous IKKα 
and AR to interact in AR-null PC-3 cells was also investigated (Figure 2.3C). PC-3 cells 
were transfected with GST-IKKα and FLAG-AR with or without 1 hour treatment of 
DHT (10 nM). GST pull-downs were performed and analyzed by immunoblotting. 
Abundant AR co-precipitated with IKKα, and was diminished by treatment with DHT. 
Interestingly, the more abundant AR band observed by immunoblotting was a slower 
migrating isoform usually considered to be hyperphosphorylated [64,65], perhaps 
indicating that IKKα prefers to associate with activated AR. 
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AR protein exists as monomers or dimers with Hsp90 chaperones ≈ 200-400 kDa 
[132,133]. IKK primarily functions through two basic signaling complexes: the IKK 
holoenzyme involved in classical NF-κB signaling and an IKKα homodimer involved in 
alternative signaling. The IKK holoenzyme is a large, ≈ 900 kDa complex consisting of 
the three IKK subunits and co-chaperone proteins [22], whereas the IKKα homodimer is 
a smaller, ≈ 300 kDa complex [26]. To investigate the nature of the IKK complex AR 
associates with, we used size-exclusion gel chromatography to fractionate LNCaP cell 
lysate. LNCaP cells were steroid-depleted, treated for 1 hour with DHT (10 nM) or 
ethanol vehicle control, and then gently lysed using a hypotonic buffer lacking detergent. 
Protein lysate was separated on a Superose 6 column and 1 mL fractions were collected 
and analyzed by SDS-PAGE and immunoblot analysis. As shown in Figure 2.3D, AR 
primarily eluted as ≈ 200-400 kDa complexes, consistent with the size of AR monomers 
or dimers including chaperone proteins. IKKα primarily eluted as ≈ 300-800 kDa 
complexes, indicating a large proportion of IKKα homodimer complexes and other large 
molecular weight complexes slightly smaller than the expected 900 kDa of the IKK 
holoenzyme. Only the shoulders of the AR and IKKα elution peaks overlap, but 
intriguingly a higher molecular weight AR isoform overlaps with the IKKα peak at ≈ 700 
kDa, consistent with an IKKα-AR complex. This higher molecular weight isoform is 
likely of the same nature as that observed in the GST pull-down from PC-3 cells (Figure 
2.3C) and may be further evidence that a small pool of highly phosphorylated AR is the 
preferred binding partner of IKKα. If so, this may indicate that IKKα inhibits AR that has 
already become activated, rather than preventing its activation. 
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Androgen induces nuclear accumulation of AR and IKKα 
In response to androgen the AR rapidly translocates from the cytoplasm to the 
nucleus where, depending on its context, it either recruits coactivators or corepressors to 
affect gene transcription [124]. Nuclear roles for IKKα have also been described [47,49–
51], prompting us to investigate which cellular compartment the IKKα-AR interaction 
exists in. We prepared cytoplasmic and nuclear extracts of steroid-depleted LNCaP cells 
treated with DHT (10 nM) for the indicated times (Figure 2.4A) and analyzed the extracts 
by immunoblotting. Treatment with DHT resulted in significant nuclear accumulation of 
AR within 15 minutes, plateauing at 30 minutes and remaining stable through 60 
minutes. Though the majority of IKKα was localized to the cytoplasm a slight nuclear 
accumulation was observed at 15 minutes reaching a maximum at 30 minutes before 
declining slightly at 60 minutes. Both AR and IKKα followed a similar trend, reaching 
maximal nuclear accumulation at 30 minutes, however, while IKKα nuclear levels 
declined by 60 minutes, AR nuclear levels persisted. Two hours after DHT treatment 
IKKα nuclear levels had decreased to basal levels while AR levels remained steady (data 
not shown). 
To investigate whether IKKα and AR associate in the nucleus we performed 
IKKα immunoprecipitations on nuclear extracts from LNCaP cells treated as above. 
Immunoblot analysis (Figure 2.4B) showed that the amount of AR co-
immunoprecipitated with IKKα increased through 60 minutes, reflecting the AR nuclear 
accumulation pattern shown in Figure 2.4A. 
These data indicate that IKKα and AR associate in the cytoplasmic compartment 
under basal conditions. Upon stimulation with androgen the IKKα-AR complex 
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translocates to the nucleus and after a short time (30-60 minutes) dissociates, allowing 
IKKα to return to the cytoplasm while AR remains in the nucleus. 
Inhibition of IKKα results in increased AR nuclear accumulation 
Since IKKα inhibition led to increased AR activity we speculated that this effect 
correlated with increased AR nuclear accumulation. LNCaP cells transfected with IKKα 
siRNA or LNCaP-shIKK cells were steroid-depleted and treated for 1 hour with DHT (10 
nM) as before, and nuclear extracts were analyzed by immunoblotting to compare 
changes in AR nuclear localization between control and IKKα knockdown cells (Figure 
2.5A, B). Knockdown of IKKα resulted in basal and DHT-induced increases in nuclear 
AR compared to control cells, mirroring the observed effects on AR target gene 
expression (Figure 2.1A, 2.2C). These data indicate that changes in AR transcriptional 
activity as a result of IKKα knockdown may be caused by changes in AR nuclear 
accumulation. 
As a second approach, we used pharmacological inhibition of IKK to assess its 
effect on AR nuclear localization over a short time course. Steroid-depleted LNCaP cells 
were treated with BAY (5 µM) for 1 hour prior to stimulating with DHT (10 nM) for 15- 
60 minutes and nuclear extracts were analyzed by immunoblotting. As shown in Figure 
2.5C, nuclear AR increased in both DMSO- and BAY-treated cells within 15 minutes and 
continued through 60 minutes, however BAY treatment resulted in significantly more 
nuclear AR. It is interesting to note that IKK inhibition not only increased basal nuclear 
AR compared to vehicle-treated cells (4-fold), but also resulted in a faster rate of AR 
nuclear accumulation (Figure 2.5C, bottom panel). 
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These results show that inhibition of IKKα in LNCaP cells resulted in increased 
nuclear accumulation of AR in both DHT-treated and untreated cells. Changes in AR 
localization correlated with the observed increases in AR transcriptional activity caused 
by IKKα inhibition, and may point to a mechanism by which IKKα attenuates AR 
activity. One result of IKKα knockdown was increased expression of AR protein (Figures 
1D, 2A) which could be a cause of the higher nuclear levels and greater activity. 
However, a 1 hour treatment with BAY had a significant effect on the rate and extent of 
AR nuclear localization in a short time span, indicating that IKKα may affect AR activity 
by modulating the kinetics of its nuclear localization.  
IKKα phosphorylates androgen receptor in vitro and in vivo 
Independent of its role in the NF-κB pathway, IKKα phosphorylates various 
proteins involved in signaling and transcriptional regulation such as β-catenin, estrogen 
receptor α, nuclear receptor coactivator 3 and histone H3 [Lamberti C, 2001; Wu RC, 
2002; Anest 2003, Yamamoto 2003; Park KJ, 2005]. We therefore investigated whether 
IKKα phosphorylated AR as a possible mechanism of regulation by performing kinase 
assays using recombinant IKKα and AR expressed in Sf9 insect cells. Incubating AR 
with IKKα and [γ-32P]-ATP resulted in robust incorporation of 32P into AR (Figure 2.6A), 
and led to an impressive shift in electrophoretic mobility and the formation of two 
distinct phospho-protein isoforms migrating above non-phosphorylated AR. 
Androgen receptor is readily phosphorylated in vivo at multiple serine residues by 
exposure of cells to growth factors and androgens [64,65,134]. Confirmation of 
additional phosphorylation induced by a specific kinase is therefore complicated when 
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using non-specific methods of visualization such as 32P-orthophosphate metabolic 
labeling or pan-serine antibodies, as gain or loss of a single phospho-serine residue is 
squelched by background signal. In order to more specifically detect phosphorylation 
induced by IKKα we employed a phospho-serine motif antibody developed by Cell 
Signaling Technology, Inc. (CST) for the purpose of screening proteins for partial 14-3-3 
binding sites. This antibody, referred to hereafter as p-Ser (2981), recognizes an R-x-Y/F-
x-pSer motif, which partially matches the IKK phosphorylation motif (see Figure 2.7A) 
[135], and is permissible for substitution of arginine with other hydrophilic amino acids 
at the -4 position (per conversations with CST technical staff). We confirmed that p-Ser 
(2981) recognized IKKα-phosphorylated AR, not non-phosphorylated AR, by 
immunoblot analysis of an in vitro kinase assay performed as before (Figure 2.6B). 
To investigate whether IKKα phosphorylated AR in a cellular context we 
expressed AR with or without IKKα in HEK 293T cells and incubated with 32P-
orthophosphate. AR was immunoprecipitated and resolved by SDS-PAGE to visualize 
32P metabolic labeling. As shown in Figure 2.6C, a single band was detected by 
autoradiography for AR expressed alone; however, co-expression with IKKα induced a 
second, slower migrating band as previously observed with in vitro assays. In addition, 
immunoblot analysis using the p-Ser (2981) antibody detected a band that corresponded 
to the upper AR isoforms, indicating that it was possibly the result of phosphorylation 
induced by IKKα. 
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Androgen receptor serine 29 is a putative IKKα substrate 
In order to map the androgen receptor site phosphorylated by IKKα, a kinase 
assay was performed with cold ATP and resolved by SDS-PAGE. The gel band 
corresponding to phosphorylated AR was excised and digested by trypsin, and peptides 
were analyzed by MALDI-TOF/TOF mass spectrometry. Three AR phospho-peptides 
were identified with > 95% confidence in both of two independent experiments: S29, S94 
and S359. Because in vitro kinase reactions can result in spurious phosphorylation, we 
compared these phosphorylation sites to the consensus IKK phosphorylation motif 
(Figure 2.7A) to estimate the likelihood that they might occur in a biological setting. Of 
the three phosphorylation sites identified, S29 has strong similarity to the published IKK 
phosphorylation motif, having -2 aromatic, +1 aliphatic and +3 acidic residues which, in 
addition, are evolutionarily conserved (Figure 2.7B). Moreover, S29 flanks the FXXLF 
motif critical for the AR NTD-LBD interaction which stabilizes AR and alters its 
transcriptional activity [He & Wilson 2000], and therefore has potential biological 
relevance. 
To investigate whether AR S29 was phosphorylated in vivo, LNCaP-shIKK cells 
were co-transfected with AR WT or S29A, and IKKα WT or K44M. AR was 
immunoprecipitated and analyzed by immunoblotting. As shown in Figure 2.7C, 
reconstitution of IKKα WT resulted in a robust phosphorylation of AR WT detected by 
p-Ser (2981), however no phosphorylation was observed for AR S29A. Moreover, in 
agreement with our previous observation, AR WT protein is decreased by co-transfection 
of IKKα WT while AR S29A is unaffected. Phosphorylation of AR S29 was also 
investigated in HEK 293T cells with similar results (Figure 2.7D). Cells were co-
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transfected with AR WT or S29/704A double-mutant and immunoprecipitated AR was 
analyzed by immunoblot analysis. AR phosphorylation detected by p-Ser (2981) was 
again increased by co-expression of IKKα WT while negligible phosphorylation was 
detected for AR S29/704A. Although a double mutant was used for this experiment, the 
sequence surrounding S704 should not be detected by p-Ser (2981). Indeed, kinase assays 
using a GST-tagged AR fragment containing this site was not recognized by p-Ser 
(2981). 
These data are compelling evidence that AR S29 is an IKKα substrate in vivo. 
Moreover, the effect of IKKα in reducing expression of AR WT but not AR S29A 
indicates that protein destabilization may be a mechanism by which IKKα regulates AR 
activity. 
AR S29A is refractory to inhibition by IKKα 
To test the effect of IKKα on AR S29A transcriptional activity, HEK 293T cells 
were co-transfected with the ARR2PB-luciferase reporter, AR WT or S29A, and IKKα, 
and were treated for 24 hours with DHT as indicated (Figure 2.8A). AR S29A showed 
greater activity than AR WT in response treatment with DHT. Co-transfection with IKKα 
somewhat reduced AR S29A activity, but in the presence of 10 nM DHT, S29A still 
retained nearly twice the activity of AR WT. Thus, mutation of the identified IKKα 
phosphorylation site confers increased transcriptional activity to AR and gives it 
resistance to the effects of IKKα overexpression. 
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2.4 Conclusions 
Herein we have defined a previously uncharacterized role for IKKα in regulating 
AR activity. We have demonstrated that IKKα physically interacts with AR and inhibits 
its transcriptional activity (Figures 1 and 3). IKKα inhibition of AR coincides with loss of 
AR protein expression (Figure 2.7C), and genetic silencing of IKKα has the opposite 
effect resulting in increased AR protein levels (Figures 1D and 2A). The observation that 
IKKα inhibition leads to increased AR protein expression has recently been corroborated 
by work in mice whereby simultaneous knockout of PTEN and IKKα lead to increased 
expression of prostate AR (H. Dan, personal communication). 
The interaction of IKKα with AR was observed in three different PCa cell lines as 
well as in HEK 293T cells, indicating that the regulatory role of IKKα may extend to 
other cell types where AR functions [136–138]. 
Intriguingly, IKKα appears to translocate to the nucleus immediately upon 
stimulation of cells with DHT (Figure 2.4), however nuclear IKKα levels decline within 
60 minutes whereas AR levels remain steady. One might speculate that IKKα translocates 
to the nucleus with AR, whereupon it plays a role in the reordering of AR dimers and 
they bind DNA and recruit coregulators [139]. Another possibility is that IKKα is 
induced to translocate to the nucleus independent of AR as one of the non-genomic 
aspects of androgen signaling [140]. 
An essential function for proper AR activity is regulated nuclear accumulation in 
response to the appropriate stimuli. We showed that genetic and pharmacological 
inhibition of IKKα resulted in increased AR nuclear accumulation (Figure 2.5). Short 
term pharmacological inhibition likely precludes regulation of AR by IKKα via changes 
32 
in gene transcription whereby IKKα would inhibit an AR feed-forward loop resulting in 
loss of its transcription. This points to a more direct mechanism of AR regulation by 
IKKα. 
In vitro kinase assays resulted in very robust phosphorylation of AR by IKKα 
(Figure 2.6) and mass spectrometry was used to map phosphorylation to a very likely 
candidate site at S29 (Figure 2.7). This site has strong sequence similarity to the 
published IKK phosphorylation motif [135], is evolutionarily conserved, and is surface 
accessible [141,142]. S29 flanks the FXXLF domain that is essential for interaction 
between the N- and C-terminal domains. This hydrophobic motif competes with AR 
coregulators for binding to a hydrophobic cleft that is formed on the AR ligand binding 
domain (LBD) when agonist is bound  and in some circumstances can lead to diminished 
AR transcriptional activity as the AR LBD AF-2 region is sequestered from coactivators. 
The FXXLF motif maintains interaction with the AF-2 via a charge clamp, mediated in 
part by AR K720 extending hydrogen bonds to S29 [141,142]. It is thus intriguing to 
speculate that the mechanism of IKKα regulation of AR lies in phosphorylation of S29, 
which would increase an already negative charge in the area surrounding S29, inducing a 
stronger interaction between S29 and K720 [143] thereby inhibiting AR activity by 
preventing interaction with coactivators.  
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Figure 2.1 IKKα attenuates AR activity.
(A) LNCaP cells were transfected with the indicated siRNA for 96 hours prior to treatment 
for 24 hours with DHT (10 nM). Total RNA was isolated and expression of AR target genes 
was evaluated by qRT-PCR. (B) LNCaP cells were pretreated for 1 hour with BAY 65-1942 
(BAY) at the indicated concentrations prior to treatment for 6 hours with DHT (10 nM). AR 
target gene expression was evaluated by qRT-PCR (C) LNCaP cells in 24-well plates were 
transfected with ARR2PB-luciferase reporter and increasing concentration of IKKa or 
IKKb (+, 0.25; ++, 0.5; +++, 1 ug), treated for 24 hours with DHT (10 nM) and luciferase 
expression was assayed. (D) LNCaP cells were transfected with siRNA to IKKa for 96 
hours prior to treatment for 6 hours with DHT (10 nM). Protein expression was analyzed 
by immunoblotting (top panel) and AR mRNA expression was analyzed by qRT-PCR 
(bottom panel).
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Figure 2.2. Stable knockdown of IKKα increases AR activity and can be rescued by 
IKKα overexpression.
LNCaP cells were selected for stable expression of control shRNA (LNCaP-shC), shRNA 
to AR or shRNA to IKKa (LNCaP-shIKK).
(A) LNCaP cells stably expressing shRNA were analyzed by immunblotting. (B) 
LNCaP-shC and LNCaP-shIKK cells were treated for 6 hours with DHT (10 nM). Total 
RNA was isolated and expression of AR target genes was evaluated by qRT-PCR. (C) 
LNCaP-shC and LNCaP-shIKK cells were transfected with ARR2PB-luciferase reporter 
and treated for 24 hours with DHT at indicated concentrations. AR activity was evaluated 
by luciferase assay.
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Figure 2.3. IKKα associates with AR in prostate cancer cell lines.
(A) LNCaP cells or (B) VCaP cells were treated for 1 hour with DHT and the indicated 
antibodies were used for immunoprecipitation and immunblotting. (C) PC-3 cells were 
transfected with FLAG-AR and GST or GST-IKKa and were treated with DHT as indi-
cated for 24 hours. GST pull-downs were performed and analyzed by immunoblotting. (D) 
LNCaP cell lysate was size-fractionated on a Superose 6 column and fractions were 
analyzed by immunoblotting.
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Figure 2.4. DHT induces robust nuclear accumulation of AR and slight accumulation 
of IKKα.
LNCaP cells were treated with DHT (10 nM) for the indicated times and cytoplasmic and 
nuclear extracts were prepared. (A) Extracts were analyzed by immunoblotting (left panel) 
and densitometry analysis was plotted (right panel). (B) IKKa was immunoprecipitated 
from extracts and immunecomplexes were analyzed by immunoblotting for the presence of 
AR.
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Figure 2.5. Knockdown or pharmacological inhibition of IKKα increases nuclear 
accumulation.
(A) LNCaP cells were transfected with control siRNA or siRNA to IKKa for 96 hours prior 
to treatment for 1 hour with DHT (10 nM). Cytoplasmic (CE), nuclear (NE) or whole cell 
(WCE) extracts were prepared and analyzed by immunoblotting. (B) LNCaP-shC and 
LNCaP-shIKK were treated for 1 hour with DHT (10 nM). Nuclear extracts were prepared 
and analyzed by immunoblotting (top panel) and densitometry analysis was plotted 
(bottom panel). (C) LNCaP cells were treated for the indicated times with DMSO or BAY 
65-1942 (BAY, 5 uM). Nuclear extracts were prepared and analyzed by immunoblotting 
(top panel) and densitometry analysis was plotted (bottom panel).
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Figure 2.6. IKKα phosphorylates AR in vitro and in vivo.
(A) In vitro kinase assay using recombinant AR and IKKa, and [gamma-32P]ATP was 
resolved by SDS-PAGE. The gel Coomassie stained (left panel), dried and exposed to 
phosphorimager screen for visualization of incorporated 32P (right panel). (B) In vitro 
kinase assay was analyzed by immunoblotting using the indicated antibodies. (C) LNCaP 
cells were metabolically labeled with [32P]orthophosphate for 1 hour, AR was immuno-
precipiated and analyzed by SDS-PAGE and immunoblotting. 32P incorporation was visu-
alized by exposing blot to film.
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Figure 2.7. AR S29 is a putative IKKα substrate.
(A) In vitro phosphorylated AR was trypsinized and analyzed by MALDI-TOF/TOF MS. 
Three peptides identified with > 95% confidence and are shown aligned to the IKK phos-
phorylation motif (top panel). The location of each phosphorylation site is shown relative 
to the AR domain organization (bottom panel). (B) Evolutionary conservation of the 
sequence surrounding S29 is shown. (C) LNCaP-shIKK cells or (D) HEK 293T cells were 
transfected with AR WT or S29A and IKKa WT or K44M. In situ AR serine phosphoryla-
tion and total protein was evaluated by immunoblotting.
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Figure 2.8. AR S29A is refractory to inhibition by IKKα.
HEK 293T cells were transfected with ARR2PB-luciferase reporter and the indicated 
expression vectors, and were treated for 24 hours with the indicated concentration of DHT. 
For each AR expression vector, luciferase activity was plotted as fold-change of the 
ethanol-treated vehicle control.
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2.5 Experimental Procedures 
Antibodies and reagents 
Antibodies were obtained from the following sources. Antibodies against IKKα 
and IKKβ were from Millipore. Anti-Flag was from Sigma-Aldrich. Anti-phosphoSer 
(2981) was from Cell Signaling Technologies. Antibodies against β-tubulin, lamin A/C, 
AR and Protein A/G PLUS agaraose were from Santa Cruz Biotechnology. HRP-
conjugated anti-mouse and anti-rabbit were from Promega. Other reagents were obtained 
from the following sources: Protease and phosphatase inhibitor cocktails were from 
Roche. All radiochemicals used were obtained from New England Nuclear. 5α-
dihydrotestosterone was from Sigma-Aldrich. BAY 65-1942 was from Theralogics, Inc. 
(Chapel Hill, NC). FLAG-AR expression vector and AR-responsive luciferase reporter 
vectors were gifts from Dr. Young E. Whang (Lineberger Cancer Center). AR mutants 
were constructed by site-directed mutagenesis of FLAG-AR in a one-step PCR using 
partial overlapping primers and Phusion Hot Start DNA polymerase (New England 
Biolabs, Ipswich, MA) [144]. 
Cell culture 
HEK 293T, LNCaP, VCaP and PC3 cells were from the American Type Culture 
Collection (ATCC). Cells were cultured in RPMI 1640 medium without phenol red 
(LNCaP and VCap) or DMEM (HEK 293T and PC3) supplemented with 10% fetal 
bovine serum and 1% antibiotic/antimycotic and were maintained at 37°C in a 5% CO2 
humidified atmosphere. Transfections were done using Lipofectamine Plus (Invitrogen) 
following the manufacturer's instructions. 
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RNAi 
Small interfering RNA (siRNA) SMARTpool IKKα, IKKβ and control siRNA 
were from Dharmacon. Each of these represents four pooled SMART selected siRNA 
duplexes that target the indicated gene. LNCaP cell lines cells were transfected using 
DharmaFECT 1 reagent (Dharmacon) according to the manufacturer's instructions. In 
brief, 20 nmol/L final concentration of siRNA was used to transfect cells at 60% to 70% 
confluency. Twenty-four hours after transfection, cells were recovered in full serum or 
were serum starved 16 h before harvest. Cells were harvested 72 to 96 hours after siRNA 
transfection. 
Cell lysis, immunoblotting, and coimmunoprecipitations. 
Cells growing in 10 cm dishes were rinsed twice with cold PBS and then lysed on 
ice for 20 min in 1 mL lysis buffer [20 mM Na-phosphate (pH 7.5), 150 nM NaCl, 2 mM 
EDTA, 10 mM glycerophosphate, 50 mM NaF, 1 mM orthovanadate, and EDTA-free 
protease inhibitors; Roche] containing 1% NP-40. After centrifugation at 13,000 × g for 
10 min, samples containing 20 to 50 μg of protein were resolved by SDS-PAGE and 
proteins were transferred to PVDF membrane (Millipore), blocked in 5% nonfat milk, 
and blotted with the indicated antibodies. For immunoprecipitation experiments, 1 ug of 
the indicated antibodies were added to the cleared cellular lysates and incubated with 
rotation for 6 to 16 h. Then, 20 μL of protein A/G PLUS agarose was added and the 
incubation continued for 1 h. Immunoprecipitates captured with protein A/G PLUS 
agarose were washed three times with the lysis buffer and boiled in 1× NuPAGE sample 
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buffer (Invitrogen) for Western blot. GST pull-downs were performed using Glutathione 
Sepharose Fast Flow (Amersham) according to the manufacturer’s directions. 
shRNA knock-down of IKKα 
pLKO.1 lentiviral vectors containing shRNA directed against IKKα or a non-
targeting shRNA were obtained from the UNC Vector Core. Lentiviral packaging vector 
psPAX2 (Addgene plasmid 12260) and envelope vector pMD2.G (Addgene plasmid 
12259) were obtained from Addgene, courtesy of Didier Trono (http://tronolab.epfl.ch/). 
Lentivirus production and LNCaP cell infection was done according to the protocol 
supplied by The RNAi Consortium 
(http://www.broadinstitute.org/rnai/public/resources/protocols). Transduced LNCaP cells 
were selected in media supplemented with puromycin (2 µg/mL) for 96 hours and cells 
were harvested for analysis by immunoblotting. Stable cell lines were maintained in 
puromycin. 
Luciferase reporter assays 
Cells were seeded in 12-well plates and were transfected with 250 ng of total 
DNA using Lipofectamine Plus (Invitrogen) following the manufacturer’s instructions. 
Cells were harvested after 24 h of transfection, and luciferase assays were performed 
using the Dual Luciferase Assay System (Promega). All transfections were performed in 
triplicate. 
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qRT-PCR 
Trizol was used to extract RNA from cells and reverse transcription using random 
hexamer primers was performed using Superscript II as per the manufacturer's protocol 
(Invitrogen). Applied Biosystems Taqman primer-probe sets were used as indicated. 
Reactions were performed on an ABI 7000 sequence detection system and relative 
quantification was determined using the ΔΔCt method. 
Size-exclusion column chromatography 
Lysates were prepared from LNCaP cells as described above. A Superose 6 
10/300 GL column (GE Healthcare) was equilibrated in lysis buffer containing 50 mM 
Tris HCl (pH 7.5), 120 mM NaCl, 1 mM NaVO3, 10 mM NaF, 1 mM DTT, 1 mM 
PMSF, 10 μg ⋅ mL−1 Aprotinin, and 10 μg ⋅ mL−1 Leupeptin using a Bio-Rad Duoflow 
liquid chromatography system. Lysate containing 4 mg of total protein was applied to the 
column and separated, running lysis buffer at 0.4 mL/min. The volume of elution for each 
molecular weight was determined using size exclusion chromatography standards (Bio-
Rad). Fractions were subjected to SDS-PAGE and immunoblot analysis with antibodies 
directed toward the indicated proteins. 
Nuclear extracts 
Cells growing in 10 cm dishes were washed 2x with ice-cold PBS, then scraped 
into 1 ml ice-cold PBS and pelleted by centrifugation at 1000xg for 4 minutes. Nuclear 
and cytoplasmic extracts were prepared according to the method of Dyer and Herzog 
[145]. 
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Kinase assays 
0.5 μg recombinant AR (courtesy of Dr. Elizabeth Wilson) was mixed with 0.5 μg 
active IKKα (Millipore) in IKK kinase buffer [20mM Hepes at pH 7.5, 10 μM ATP, 10 
mM MgCl2,10mM β-glycerophosphate, 10 mM NaF, 1mM DTT, supplemented with 
Complete Protease Inhibitor (Roche) and phosphatase inhibitor cocktail (Sigma-Aldrich)] 
with [γ-32P]-ATP (0.5 µCi for per kinase reaction). Kinase assays were performed for 30 
min at 30°C in 30 µL of IKK kinase buffer. To stop the reaction, 8 µL of 4× SDS sample 
buffer was added to each reaction, which was boiled for 10 min. The reaction was then 
separated by 4%–12% SDS- PAGE and dried gels were exposed to film to assess 32P 
incorporation into AR by autoradiography. 
Phosphopeptide mapping 
Proteins were separated by SDS-PAGE and digested by trypsin, and tryptic 
peptides were used to identify proteins by peptide mass fingerprinting on a MALDI 
TOF/TOF 4800 mass analyzer (AB SCIEX). MS/MS spectra were searched against the 
Uniprot/Swiss-Prot database with ProteinPilot™ software version 3.0 (AB SCIEX) for 
peptide and protein identifications with an emphasis on phosphorylation. 
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CHAPTER III 
KINOME ADAPTATIONS IN DRUG RESISTANT LEUKEMIA 
 
3.1 Overview 
Protein kinases play key roles in oncogenic signaling and are a major focus in the 
development of targeted cancer therapies. Imatinib, a BCR-Abl tyrosine kinase inhibitor, 
is a successful front-line treatment for chronic myelogenous leukemia (CML). However, 
resistance to imatinib may be acquired by BCR-Abl mutations or hyperactivation of Src 
family kinases such as Lyn. We have used novel multiplexed kinase inhibitor beads 
(MIBs) and quantitative mass spectrometry (MS) to compare kinase expression and 
activity in an imatinib-resistant (MYL-R) and -sensitive (MYL) cell model of CML. 
Using the MIB/MS technology, expression and activity changes of over 150 kinases were 
quantitatively measured from a variety of protein kinase families. Statistical analysis of 
experimental replicates assigned significance to 35 of these kinases which we refer to as 
the MYL-R kinome profile. MIB/MS and immunoblot analysis confirmed the over-
expression and activation of Lyn in MYL-R cells and identified additional kinases with 
increased (e.g., MEK, ERK, IKK, PKCβ, NEK9) or decreased (e.g., Abl, Kit, JNK, 
ATM, Yes) abundance or activity in these cells. Inhibiting Lyn with dasatinib or by 
shRNA-mediated knockdown blocked the phosphorylation of MEK and reduced the 
phosphorylation of IKK. Because MYL-R cells showed elevated NF-κB signaling 
relative to MYL cells, as demonstrated by increased IκBα and IL-6 mRNA expression, 
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we tested the effects of an IKK inhibitor (BAY 65-1942). MIB/MS and immunoblotting 
revealed that BAY 65-1942 increased MEK/ERK signaling and that this increase was 
prevented by co-treatment with a MEK inhibitor (AZD6244). Furthermore, the combined 
inhibition of MEK and IKKα resulted in reduction of IL-6 mRNA expression, synergistic 
loss of cell viability and increased apoptosis. Thus, MIB/MS analysis identified MEK and 
IKK as important downstream targets of Lyn, suggesting that co-targeting these kinases 
may provide a unique strategy to inhibit Lyn-dependent imatinib-resistant CML. These 
results demonstrate the utility of MIB/MS as a tool to identify dysregulated kinases and 
to interrogate kinome dynamics as cells respond to targeted kinase inhibition.  
3.2 Introduction 
The constitutively active BCR-Abl tyrosine kinase is the product of the reciprocal 
translocation of chromosomes 9 and 22 and the causative oncoprotein in over 95% of 
chronic myeloid leukemia (CML) cases [7]. Imatinib (Gleevec™), a small molecule 
ATP-competitive inhibitor of BCR-Abl, is an effective front-line treatment for CML and 
has established the concept of targeted kinase inhibition as a viable strategy for cancer 
therapy [81]. However, whereas the majority of newly diagnosed CML patients undergo 
remission, some patients are refractory to imatinib therapy and others who initially 
respond will eventually develop imatinib resistance [82–84]. 
Multiple mechanisms of cellular resistance to imatinib have been described and 
include BCR-Abl-dependent mechanisms such as protein overexpression or expression of 
inhibitor-resistant mutations in the BCR-Abl kinase domain, such as the T315I 
“gatekeeper mutation” [85]. This mutation reduces the affinity of tyrosine kinase 
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inhibitors while increasing the leukemogenic signaling of BCR-Abl [86–88]. Resistance 
also arises from BCR-Abl-independent mechanisms such as alterations in drug import or 
export that affect intracellular imatinib levels [89–92], clonal evolution as the result of 
additional genetic abnormalities [93,94], and up-regulation of alternative signaling 
pathways [87,95]. 
Upregulation of kinases such as AKT or Src family kinases (SFKs) have been 
implicated in imatinib resistance whereby these kinases drive alternative cell survival and 
proliferation signaling [85,96–99]. For instance, hyper-activation of Lyn or Hck has been 
associated with imatinib resistance in CML patients and cell culture models [100–103], 
albeit the mechanisms by which these kinases contribute to imatinib resistance is not well 
understood. Moreover, a recent study reported that SFKs are frequently involved in 
promoting inhibitor-resistant CML, even after successful inhibition of BCR-Abl activity 
[104]. 
Large-scale proteomics studies have analyzed differential protein expression and 
phosphorylation in drug-resistant leukemia [106–109]. The expression and activation 
state of protein kinases (i.e., the kinome) may contribute significantly to the cellular 
adaptation to drug resistance, and recent technologies have been developed to study the 
kinome en masse. One such technology is the development of kinase inhibitor-conjugated 
beads used for the enrichment of protein kinases [113,114]. These broad spectrum kinase 
inhibitors target the ATP-binding pocket and allow the unbiased capture of kinases, 
including low abundant kinases. Quantitative methods of mass spectrometry (e.g., 
iTRAQ and SILAC) are subsequently applied to evaluate kinome changes on a global 
scale [112–114,146,147]. We have previously applied a methodology using multiplexed 
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kinase inhibitor-conjugated beads (MIBs) combined with methods of quantitative mass 
spectrometry (MIB/MS) to examine kinome reprogramming in triple-negative breast 
cancer in response to MEK inhibition [148]. 
In this study, we applied the MIB/MS strategy to investigate kinome adaptations 
in a cell line model of Lyn-driven, imatinib-resistant CML (MYL-R) and compared this 
to its imatinib-sensitive counterpart (MYL) [101]. Quantitative proteomic profiling by 
iTRAQ and LC TEMPO MALDI-TOF/TOF identified multiple kinome differences in the 
imatinib-resistant MYL-R cells. These differences included upregulation of Lyn, as well 
as kinases involved in the MEK/ERK (MEK2, ERK2) and NF-κB (IKKα) pathways. We 
found that pharmacological and RNAi-mediated inhibition of Lyn reduced the activity of 
MEK2 and IKKα, implicating these pathways as mediators of Lyn-driven imatinib-
resistance. 
Furthermore, we used the MIB/MS strategy to examine the kinome responses of 
MYL-R cells to targeted inhibition of MEK and IKK. The kinome response profiles 
indicated that targeted inhibition of these kinases led to upregulation of pro-survival 
kinases, however combined inhibition prevented this response. Moreover, the combined 
targeted inhibition of MEK and IKK successfully overcame MYL-R drug resistance and 
led to significantly reduced cell viability and induction of apoptosis. Thus, this study 
demonstrates that MIB/MS kinome profiling is a powerful tool both for detecting 
dysregulated kinases and for identifying targeted therapies for the treatment of drug-
resistant leukemia. 
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3.3 Results 
Use of Multiplexed Inhibitor Beads (MIBs) to Analyze the Kinome of Drug Sensitive 
and Resistant Leukemia Cells 
We applied the MIB/MS methodology described previously [148] to examine 
differences in the kinomes between an imatinib-resistant, Lyn-dependent CML cell line 
(MYL-R) and its imatinib-sensitive counterpart (MYL) [101]. Kinases were isolated from 
MYL and MYL-R cell lysates by MIBs enrichment, which captures a broad range of 
kinases as a function of their expression level and activation state [114,148–150]. Kinase 
expression and activity was quantitatively profiled by labeling trypsin-digested MIB 
eluates with iTRAQ isobaric mass tags, and analyzing labeled peptides by MALDI 
TOF/TOF mass spectrometry (MIB/MS) as described earlier [148]. 
The MS/MS spectra from three independent MIB/MS experiments were analyzed 
by ProteinPilot™ (AB Sciex, Framingham, MA) using the ProGroup™ algorithm for 
protein identification. We identified a total of 165 kinases with > 95% confidence, 
(ProteinPilot™ Unused ProtScore > 1.3), representing each protein kinase group and 
several non-protein kinases involved in regulating metabolic processes (Figure 1A, Table 
S1). Over 150 of these kinases were quantified, revealing multiple changes in kinase 
abundance in MYL-R compared to MYL cells (Figure S1A, Table S1). To visualize the 
trend in kinase abundance changes we set a cutoff of ± 1.5-fold; this threshold was based 
on previous analysis of technical replicates in our lab, using guidelines proposed by 
Unwin, et al. [151]. According to these criteria, ≈ 9% of quantified kinases were 
increased in abundance in MYL-R cells and nearly twice as many were decreased while 
the majority of kinases remained unchanged (Figure 1B). 
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As a complement to iTRAQ quantification, we performed a MIB/MS experiment 
comparing SILAC-labeled MYL and MYL-R cells. As shown in Supplementary Figure 
S1B, S1C, both quantification methods revealed similar trends in kinase profiles, in terms 
of kinase identity and direction of change. Quantification by SILAC showed that ≈ 22% 
of kinases were increased in abundance in MYL-R cells while ≈ 16% of kinases were 
decreased. This observation agrees with previous reports that iTRAQ tends to 
underestimate differences in protein abundance [152,153]. 
In order to establish the kinome profile for MYL-R relative to MYL cells, we 
pooled the kinase abundance ratios from three MIB/MS experiments, combined their p-
values and then corrected for multiple hypothesis testing expressed as a q-value 
according to the Benjamini-Hochberg method [154]. Reasoning that MIB/MS is a 
discovery tool to be validated by other methods such as immunoblotting, we accepted all 
quantified kinases with a q-value < 0.2. The relative abundances of the 35 kinases that 
met these criteria are referred to as the MYL-R kinome profile (Figure 1C). This profile 
shows that the kinases increased in MYL-R relative to MYL were: AMPK (AAKG1), 
DNA-PK (PRKDC), ERK2 (MK01), IKKα, Lyn, MEK2 (MP2K2), Nek9, PKCβ 
(KPCB), PRPK and RIPK2. Those decreased in MYL-R relative to MYL were: Abl2, 
ASK1 (M3K5), ATM, BMP2K, CDK2, CDK5, CDK6, CK2a’ (CSK22), CK2b 
(CSK2B), dCK, FAK1, Fes, GSK3a, HGK (M4K4), INSR, Jak1, JNK1 (MK08), c-Kit, 
MLTK, NDKM, RSK1 (KS6A1), Tec, TTK, Tyk2, Yes. These data demonstrate that the 
MIB/MS approach identified significant and quantitative differences between the 
kinomes of MYL and MYL-R cells. 
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Validation of MIB/MS Kinome Results by Immunoblotting 
To confirm changes in specific kinases detected by MIB/MS, lysates from MYL 
and MYL-R cells were analyzed by immunoblotting to examine the expression and 
phosphorylation of candidate kinases in the two cell lines. As shown in Figure 2A, 
reduced amounts of ATM, BCR-Abl, c-Kit and JNK1 protein were detected in MYL-R 
compared to MYL lysates, confirming the lower total expression of these kinases 
detected by MIB/MS analysis. By contrast, kinases detected as increased by MIB/MS 
(PKCβ, Lyn, FAK1, IKKα, MEK2, and ERK2) were observed to have greater expression 
or activation loop phosphorylation in MYL-R cells, reflecting the ability of MIBs to 
capture kinases based both on abundance and activity [148]. Immunoblot analysis 
showed that Lyn and PKCβ protein was higher in MYL-R compared to MYL (Figure 2B, 
left panel), whereas the total amount of FAK1, IKKα, MEK2 and ERK2 was comparable 
between the two cell lines (Figure 2B, right panel). Interestingly, immunoblot analysis 
using antibodies to detect the phosphorylation of the activation loops (IKKα, MEK2 and 
ERK2) or autophosphorylation sites (Lyn, PKCβ, FAK1) indicated increased activation 
of each of these kinases in the MYL-R samples. 
We further investigated the activity-dependent binding of kinases to MIBs by 
performing pull-down assays to compare the amount of kinases bound to MIBs with or 
without phosphatase treatment. MYL and MYL-R cell lysate was incubated with or 
without calf intestinal alkaline phosphatase, incubated with MIBs and bound proteins 
were eluted with SDS sample buffer and analyzed by immunoblot. Analysis of cell 
lysates (Figure S2, top) showed that treatment with alkaline phosphatase eliminated 
phospho-IKKα while levels of total IKKα were unaffected. Analysis of MIBs eluate for 
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levels of total IKKα, Lyn and MEK2 (Figure S2, bottom) showed that a greater amount 
of these kinases were captured from MYL-R lysate than from MYL lysate, correlating 
with the increased kinase abundance and phosphorylation in MYL-R detected by 
MIB/MS (Figure 1C) and immunoblot analysis (Figure 2B). Treatment of MYL-R lysates 
with alkaline phosphatase eliminated the binding of IKKα, Lyn and MEK2 to MIBs, 
demonstrating the influence of kinase activity on MIB binding. 
As demonstrated above, a limitation of MIB/MS for global kinome analysis is that 
validation by immunoblotting may require the use of high quality phospho-specific 
antibodies to distinguish between total kinase levels and activated kinase that is 
preferentially captured by MIBs. Therefore, to allow further validation using available 
pan-antibodies we performed MIBs pull-down assays to compare the amount of kinases 
captured from MYL and MYL-R cell lysates. Cell lysates were incubated with MIBs, 
bound kinases were eluted with SDS sample buffer, and eluates were analyzed by 
immunoblot using antibodies directed against total protein. We examined 12 kinases 
captured from MYL and MYL-R cell lysates and in each case the relative kinase amount 
corroborated the MYL-R kinome profile. The kinases observed to be decreased in MYL-
R eluates were ASK1, Jak1, MLTK, Yes, GSK3α, CDK2 and dCK (Figure 2C, left 
panel), and the kinases observed to be increased in MYL-R eluates were NEK9, RIPK2, 
IKKα, Lyn and ERK (Figure 2C, right panel). The latter three kinases were included to 
verify that this approach would show differences among cell lines in kinases with 
changes in total expression (Lyn) as well as changes only in activation state (IKKα, 
ERK). Because the antibody used to detect phospho-IKKα also recognizes phospho-
IKKβ, we separated proteins from cell lysates on a low-percentage polyacrylamide gel 
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and performed immunoblot analysis to compare the migration of phospho-IKK with total 
IKKα and IKKβ (Figure S3). This data indicated a significant increase in the 
phosphorylation of IKKα, but not IKKβ, in MYL-R cells and confirmed the selective 
increase in IKKα binding detected by MIB/MS. 
In total, we confirmed the expression level and activity changes of 19 of the 35 
kinases found in the MYL-R kinome profile. These results thus demonstrate the ability of 
MIB/MS to detect specific changes in kinase abundance and activity, and validate it as a 
tool to profile changes in the kinome. 
Lyn kinase drives activation of MEK and IKKα in MYL-R cells 
Applying MIB/MS to study kinome adaptations in MYL-R identified a significant 
increase in Lyn, a kinase associated with some types of imatinib-resistant CML 
[100,101]. Consequently, we asked whether we could use the kinome profile of MYL-R 
cells to identify other kinases regulated by Lyn. Kinases increased in MYL-R cells 
include those in the MEK/ERK pathway [MEK2 (MP2K2) and ERK2 (MK01)] and the 
NF-κB pathway (IKKα), both of which could potentially be activated by Lyn [155–158]. 
 In order to investigate the effect of Lyn on activation of these kinases, we treated 
MYL-R cells with varying amounts (0.1-10 nM) of the dual Abl/Src family kinase (SFK) 
inhibitor dasatinib for 1 hour and assessed the phosphorylation status of Lyn, MEK and 
IKKα by immunoblot analysis. As shown in Figure 3A, dasatinib treatment nearly 
abolished Lyn and MEK phosphorylation, while having a moderate effect on IKKα 
phosphorylation (≈ 60 % reduction). These results suggest that Lyn is responsible for 
activation of MEK in MYL-R cells and that it may partially regulate IKKα activity. 
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We used MIB/MS to investigate the MYL-R kinome response to inhibition of Lyn 
by dasatinib. To test the initial kinome response to dasatinib, we treated MYL-R cells 
with dasatinib for 1 hour at 10 nM, a concentration sufficient to completely inhibit Lyn 
(data not shown), and then analyzed the lysates by MIB/MS as described earlier. Kinase 
abundance ratios were calculated for dasatinib treatment compared to DMSO control, 
resulting in the quantification of 139 kinases as shown in Figure S4 and Table S2. 
Kinases decreased after dasatinib treatment included established dasatinib targets such as 
the SFKs Lyn and Yes, Abl2, BTK and CSK [159–161]. Other kinases observed to be 
decreased have either not been reported as dasatinib targets, or have an affinity for 
dasatinib reported to be lower than 10 nM [112,146], indicating that they may be indirect 
targets of dasatinib treatment. These included kinases in the MEK/ERK pathway [B-Raf, 
MEK2 (MP2K2), ERK2 (MK01), RSK1 (KS6A1)] as well as a kinase known to activate 
IKK (RIPK2) [162,163]. 
Because of concerns about the selectivity of dasatinib, we performed Lyn 
knockdown using lentiviral shRNA as described in Material and Methods. As shown in 
Figure 3B, transduction of MYL-R cells with Lyn shRNA reduced total and 
phosphorylated Lyn by ≈ 65% and ≈ 50%, respectively. Lyn knockdown resulted in 
reduced phosphorylation of both MEK (≈ 57%) and IKKα (≈ 75%), as observed with 
dasatinib, supporting the involvement of Lyn signaling in the activation of MEK and 
IKKα in MYL-R cells. 
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MYL-R exhibit an increased level of NF-κB signaling 
IKKα is a subunit of the IKK complex, which serves to activate the transcription 
factor NF-κB, but can also phosphorylate other proteins involved in signaling and 
transcriptional regulation [47,49–51,164–166]. To establish whether elevated IKKα 
activity correlated with increased NF-κB activity in MYL-R cells, we isolated total RNA 
from MYL and MYL-R cells and evaluated the mRNA levels of two established NF-κB 
target genes, IκBα and IL-6 [167], using real-time quantitative RT-PCR (qRT-PCR). 
Both IκBα and IL-6 were overexpressed 2.6- and 5.7-fold, respectively, in MYL-R 
relative to the MYL cells (Figure 4A), consistent with increased NF-κB signaling in 
MYL-R cells. To investigate the role of IKKα in NF-κB activation in MYL-R cells, we 
examined the phosphorylation of the NF-κB p65 subunit at Ser536, an IKK 
phosphorylation site and marker of NF-κB activity. As shown in Figure 4B, basal 
phosphorylation of p65 was elevated ≈ 5-fold in MYL-R cells compared to MYL cells. 
Furthermore, p65 phosphorylation was blocked by treating cells with a selective IKK 
inhibitor, BAY 65-1942 [130]. 
To further investigate the ability of BAY 65-1942 to inhibit NF-κB signaling in 
MYL-R cells, we treated cells with the inhibitor (10 μM) for 12 hours and then measured 
IκBα and IL-6 mRNA expression by qRT-PCR analysis as before. MYL-R cells treated 
with BAY 65-1942 showed ≈ 2-fold decrease in IκBα expression compared to the 
DMSO-treated control cells (Figure 4C). Surprisingly, BAY 65-1942 had the opposite 
effect on IL-6 expression, leading to a 4.4-fold increase over vehicle-treated cells (Figure 
4C).  
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Kinome response to targeted MEK and IKK inhibitor treatment 
Since our data showed that both the MEK and IKK pathways were activated in 
MYL-R cells, we used MIB/MS and immunoblot analysis to examine the kinome 
response to targeted inhibition of these pathways, individually and in combination. 
Inhibitors of MEK (AZD6244) and IKK (BAY 65-1942) were used at their IC50 
concentrations, as determined by a 48 hour MTS assay, which achieved sufficient 
inhibition of kinase activity (as shown in Figures 4B, 5B). As such, MYL-R cells were 
treated for 24 hours with AZD6244 (5 μM), BAY 65-1942 (10 μM), or a combination of 
these inhibitors at the same concentrations. To establish the MYL-R kinome response to 
targeted MEK and IKK inhibition, lysates from these cells were analyzed by MIB/MS as 
described earlier, and kinase abundance ratios were calculated for each drug treatment 
compared to DMSO control. In two independent experiments, 111 kinases were 
quantified (Figure S6, Table S3). Comparing the kinases that were differentially affected 
by either MEK or IKK inhibition revealed multiple changes in the MIB/MS capture of 
kinases in the MEK/ERK pathway (Figure 5A). MEK inhibition resulted in significant 
decreases in the retention of B-Raf (0.32-fold), MEK1 (0.55-fold) and RSK1 (0.30-fold) 
as expected. Conversely, IKK inhibition resulted in significant increases in B-Raf (1.26-
fold) and RSK1 (1.54-fold) bound to MIBs. Treating cells with a combination of the two 
inhibitors reversed the effects of BAY 65-1942 and decreased B-Raf (0.37-fold), MEK1 
(0.61-fold) and RSK1 (0.68-fold) binding. Thus, the MIB/MS analysis of the MYL-R 
kinome response to targeted IKK inhibition revealed an unexpected increase in the 
MEK/ERK pathway that was negated by simultaneous inhibition of both kinases. 
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To confirm the increased MEK/ERK activity in MYL-R cells in response to BAY 
65-1942, we treated cells with MEK and IKK inhibitors for 24 hours and analyzed cell 
lysates by immunoblotting. As shown in Figure 5B, treatment of cells with AZD6244 (5 
μM) did not decrease phosphorylation of MEK but induced a significant loss in ERK 
phosphorylation. In agreement with the MIB/MS results, treatment of cells with BAY 65-
1942 (10 μM) increased MEK/ERK activation as shown by a significant increase in ERK 
phosphorylation. By contrast, the combination of AZD6244 (5 μM) and BAY 65-1942 
(10 μM) resulted in an overall decrease in ERK phosphorylation.  
Since activation of MEK/ERK has been reported to increase IL-6 production 
[168], we investigated whether treating cells with a combination of MEK and IKK 
inhibitors would reverse the increase in IL-6 expression induced by IKK inhibition. 
MYL-R cells were treated for 24 hours with AZD6244 (5 μM), BAY 65-1942 (10 μM) or 
dasatinib (1 nM) and RNA was isolated in order to measure IκBα and IL-6 expression by 
qRT-PCR (Figure 5C). Incubation with BAY 65-1942 resulted in ≈ 2-fold decrease in 
IκBα mRNA expression, either alone or in combination with AZD6244. IκBα mRNA 
expression was not affected by AZD6244 treatment nor with dasatinib treatment, in 
agreement with the modest effects of dasatinib on IKKα phosphorylation (Figure 3). 
Consistent with our observation that BAY 65-1942 activated MEK, IL-6 mRNA 
expression was increased ≈ 2-fold after BAY 65-1942 treatment and this increase was 
prevented by co-incubation with AZD6244. Dasatinib also significantly reduced IL-6 
expression, consistent with inhibition of MEK by dasatinib. These results indicate that 
activation of the MEK/ERK pathway in response to BAY 65-1942, as predicted by 
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MIB/MS, is responsible for increased IL-6 production and can be prevented by the 
combined inhibition of MEK and IKK. 
Targeted inhibition of kinases detected by MIB/MS leads to induction of apoptosis 
Our data suggested that the combined inhibition of both MEK and IKK prevented 
much of the response observed after individual MEK or IKK inhibition. We next asked 
whether combined inhibition of MEK and IKK would be more effective at inducing cell 
death than inhibition of either kinase alone. The effects of combined kinase inhibition on 
MYL-R cell viability was determined by MTS assay. Cells in exponential growth and 
were treated with AZD6244 (5 μM), BAY 65-1942 (10 μM), a combination of both, or 1 
nM dasatinib. Drug and media were replenished after 24 hours, and cell viability was 
assayed 48 hours after initial treatment according to standard MTS assay procedure. As 
shown in Figure 6A, treatment with AZD6244 and BAY 65-1942 reduced MYL-R cell 
viability by ≈ 50% and 37%, respectively, compared to DMSO-treated cells, whereas 
combined treatment with AZD6244 plus BAY 65-1942 reduced cell viability by ≈ 84%. 
As a comparison, dasatinib treatment led to a nearly 95% reduction in MYL-R cell 
viability, consistent with inhibition of Lyn in these cells.  
Drug synergy was assessed using CompuSyn software to calculate a combination 
index (CI) of drug effects at various doses, according to the Chou-Talalay median-effect 
principle (where CI < 1 indicates synergism) [169–171]. MYL-R cells were treated with 
three-fold serial dilutions of AZD6244 and BAY 65-1942, singly or in combination at a 
constant ratio, and MTS assays were performed as above. AZD6244 and BAY 65-1942 
demonstrated synergistic inhibition of cell viability at the dose combination used in 
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Figure 2A (5 μM AZD6244 + 10 μM BAY 65-1942), which correlates with IC75 (CI = 
0.48 ± 0.01). Synergism was also indicated at the IC50 (CI = 0.56 ± 0.09) and IC90 (CI = 
0.46 ± 0.02) dose combinations reported by the software. (CI values are the mean of three 
independent experiments, ± standard deviation.)To determine whether targeted inhibition 
of MEK and IKK increased apoptosis we assayed inhibitor treated cells for caspase-3/7 
activation. MYL-R cells were treated as described above and after 24 hours cells were 
harvested and lysed with CHAPS buffer in order to gently release activated caspases. 
Caspase 3/7 activity was measured by incubating cell lysates with a caspase 3/7 substrate 
(Ac-DEVD-AMC) and measuring the amount of AMC liberated by fluorimetry. As 
shown in Figure 6B, AZD6244 and BAY 65-1942 treatment induced 2- and 1.3-fold 
caspase 3/7 activation, respectively, compared to the DMSO-treated cells. Treatment with 
a combination of AZD6244 plus BAY 65-1942 led to a 3.2-fold increase in caspase 3/7 
activity, which was comparable to the amount of caspase 3/7 activation induced by 
dasatinib. 
To confirm that the targeted kinase inhibition resulted in MYL-R apoptosis, we 
analyzed the levels of cleaved poly(ADP-ribose) polymerase (PARP) by immunoblotting 
(Figure 6C). MYL-R cells were treated as before and harvested after 48 hours, the same 
time point at which cell viability was measured. This analysis showed the presence of 
PARP cleavage in cells treated with AZD6244 alone, however cells treated with a 
combination of AZD6244 and BAY 65-1942 or with dasatinib showed increased PARP 
cleavage and a significant loss of total PARP, indicating that the apoptotic process had 
progressed further with these two treatments. Additionally we tested for the presence of 
cleaved caspase 3. The results in Figure 6C confirm that treating MYL-R cells with a 
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combination of AZD6244 and BAY 65-1942 was nearly as effective as dasatinib in 
activating caspase activity, and was significantly more effective than treating with either 
inhibitor alone. 
These results demonstrate that the MIB/MS kinome profile identified MEK and 
IKK as important mediators of survival, and that combined inhibition of MEK and IKK 
effectively induced apoptotic cell death in drug-resistant CML. We have also observed 
increased MEK and IKK phosphorylation that correlates with Lyn amplification and 
activation in the HL-60 acute myeloid leukemia cell line differentiated with all-trans-
retinoic acid (ATRA) (Figure S7). ATRA-differentiated HL-60 cells exhibit resistance to 
cytotoxic drugs and death receptor-mediated cell death, and have increased Lyn 
expression which is required for their survival [172–175], raising the possibility that the 
MEK/ERK and IKK pathways may play a role in ATRA-induced drug resistance. 
3.4 Discussion 
Herein we describe the application of a recently developed kinase affinity 
technology (MIB/MS) to investigate kinome adaptations in an imatinib-resistant CML 
cell line. Our ultimate aim was to develop and apply this technology to obtain insight into 
the molecular adaptations of drug-resistant cells with the goal of using this information to 
rationally target kinases contributing to imatinib resistance. Using multiple, structurally 
distinct kinase inhibitors, this MALDI-TOF/TOF MS based technology provides a high 
throughput, quantitative approach to interrogate the kinome as described earlier [148]. 
Importantly, these studies demonstrated that kinase binding to MIBs was a function of 
both activity and expression, hence MIBs can be used to profile the “activation state” of 
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the kinome. Our studies confirm this and show the utility of the MIB/MS approach to 
study kinome adaptations in drug resistant cells and have identified significant 
quantitative differences in the kinomes of MYL and MYL-R cells (Figure 1, S1). 
Multiple peptides with 95% confidence were obtained from these samples, allowing the 
quantification of multiple kinases simultaneously. 
Lyn is a SFK with an established role in promoting the survival of imatinib-
resistant CML cells from patients and cell lines such as MYL-R independently of BCR-
ABL mutations [95,100–102,104,176–178]. MIB/MS confirmed the increased expression 
and activation of Lyn in MYL-R cells as reported initially by Ito [101] and others [179]. 
Using MIB/MS we also detected a substantial number of kinases not previously reported 
to be increased or decreased in imatinib-resistant cells. In three independent experiments 
our MIB/MS approach identified and quantified a total of 153 kinases, nearly 50% of the 
estimated expressed kinome [148,180]. For the purpose of establishing a MYL-R kinome 
profile, the significance of these quantifications was established through statistical 
analysis and only kinase abundance ratios with Benjamini-Hochberg q-values < 0.2 were 
considered to be significantly different.  
The MYL-R kinome profile revealed up-regulation of multiple kinases involved 
in cell growth, anti-apoptosis and stress signaling. This included kinases such as MEK2 
and ERK2 (MEK/ERK pathway), IKKα (NF-κB pathway) and others NEK9 (mitotic 
regulation), PRPK (TP53-activating kinase), AAKG1 (AMP-activated protein kinase), 
RIPK2 (innate immune response) and PRKDC (DNA-dependent protein kinase/DNA 
damage response). The increased binding of MEK2 and IKKα to MIBs was confirmed to 
be activity dependent by two independent criteria. First, a greater amount of the 
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phosphorylated kinases was captured on MIBs as determined by immunoblotting and 
second, this binding was reversed by phosphatase treatment of the samples (Figure S2). 
These studies illustrate that kinase capture measured by MIB/MS is both a function of 
changes in kinase expression and kinase activation as reported earlier [148]. In support of 
a pivotal role for Lyn in MYL-R cells, treatment with dasatinib, a Lyn and SFK inhibitor, 
prevented the binding of a large number of these kinases to MIBs (Figure S4). Further 
evidence for Lyn as a regulator of the MEK/ERK pathway was supported by our shRNA 
data and is consistent with earlier observations demonstrating Lyn as an activator of 
MEK [158]. By contrast, the mechanism by which Lyn regulates IKKα or other kinases 
in MYL-R cells (NEK9, PRPK etc.) remains to be elucidated. We also detected a 
significant increase in PKC activity, both by MIB/MS and by immunoblotting. PKC 
has been shown to regulate anti-apoptotic responses in myeloid leukemias [181], however 
inhibition of PKC with bryostatin did not affect the viability of MYL-R cells 
(unpublished observations).  Interestingly, a recent proteomics study profiling kinase 
expression in drug-refractory head and neck squamous cell carcinoma identified a 
number of the same kinases (Lyn, MEK, NEK9) as we did in MYL-R cells, suggesting 
that these may represent a drug resistant kinome profile [182].  
Considerable insight may also be obtained from the MIB/MS analysis of the 
kinases decreased in MYL-R cells. Approximately twice as many kinases were decreased 
as increased in the MYL-R cells and this was confirmed by both iTRAQ and SILAC 
quantification methods. Reduced levels of some of these kinases may be expected given 
that they are direct targets for inhibition by imatinib (Abl, c-Kit) and MYL-R cells were 
generated by continuous exposure of MYL cells to imatinib [101]. Interestingly, the 
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decreased binding of JNK (MK08) and kinase regulators of JNK [ASK1 (M3K5), HGK 
(M4K4), ZAK (MLTK)], indicate a decrease in this pro-apoptotic regulatory pathway in 
MYL-R cells [183,184]. Down-regulation of these kinases could potentially contribute to 
the anti-apoptotic properties of MYL-R cells. Decreased NDKM (nucleoside diphosphate 
kinase) or dCK (deoxycytidine kinase) may also contribute to the reduced sensitivity of 
MYL-R cells to nucleoside analogs (gemicitabine, Ara-C) that we observed previously 
(unpublished observations). The marked reduction of ATM may result from the reduced 
BCR-Abl protein in MYL-R cells as ATM has been shown to directly interact with Abl 
kinase [185,186], however the effect of this on cell survival is unclear.  
NF-κB plays a key role in regulating anti-apoptotic reactions and responses to 
chemotherapy [15]. Because we detected increased IKKα and NF-κB signaling in MYL-
R cells we examined the specific effects of targeting this pathway. BAY 65-1942 is a 
selective inhibitor of IKK (alpha and beta isoforms) and an inhibitor of NF-κB responses 
[130,187,188]. While BAY 65-1942 effectively blocked IκBα expression as expected, it 
stimulated a surprising increase in IL-6 expression in MYL-R cells that correlated with 
increased ERK phosphorylation. MIBs analysis of MYL-R cells treated with BAY 65-
1942 confirmed the activation of the MEK/ERK pathway and an increase in B-Raf, ERK 
(MK01) and RSK (KS6A1) binding was detected (Figure S6). Since our results suggested 
that BAY 65-1942 triggered a compensatory activation of the MEK/ERK pathway, we 
examined the effects of co-targeting these pathways. The MIB/MS analysis of the 
response to BAY 65-1942 and the MEK inhibitor AZD6244 was complex, with many 
kinases significantly lowered, including B-Raf, MEK (MAP2K1), and RSK1 (KS6A1) 
after combination treatment (Figures 5A, S6). Importantly, the combination of these 
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inhibitors not only prevented the BAY 65-1942-stimulated increase in IL-6 and phospho-
ERK, but substantially reduced cell viability and increased apoptosis as determined by 
PARP cleavage and caspase 3/7 activation. Thus these studies demonstrate that MIB/MS 
profiling provided an experimental rationale for co-targeting the IKK and MEK/ERK 
pathways and provided insight into why combined inhibition was synergistic compared to 
inhibition of  MEK or IKK alone. 
In summary, the results presented here demonstrate a unique approach to 
comprehensively determine kinome changes in cells with acquired drug resistance.  
These methods are expected to be widely applicable to other cell models and we have 
recently obtained kinome profiles from myeloid cells purified directly from CML or 
AML patient blood (unpublished observations). While previous studies have identified 
the importance of Lyn in imatinib-resistant CML [100,101,177], our studies further 
identified dysregulation of two well characterized kinase pathways (MEK/ERK and 
IKK/NF-κB) and demonstrated their relationship to activation of Lyn.  Moreover, we 
identified significant changes in a number of less well-studied kinases including NEK9, 
RIPK2, PRPK and PRKDC. Further studies will be necessary to elucidate the importance 
of these kinases in the development of acquired drug resistance. 
  
Figure 3.1. Application of MIB/MS to analyze the kinomes of drug-sensitive and 
resistant leukemia cells.
Kinases from MYL and MYL-R cells were affinity enriched with multiplexed inhibitor 
beads and quantified by LC-MALDI TOF/TOF mass spectrometry (MIB/MS). Results 
from three independent experiments were pooled as described in Materials and Methods. 
(A) Over 150 kinases were quantified from MYL-R relative to MYL cells across a broad 
spectrum of kinase families, as depicted in the phylogenetic tree of the human protein 
kinase superfamily. Yellow and blue dots signify kinases that were increased or decreased 
in abundance, respectively, in MYL-R relative to MYL cells while gray dots signify 
kinases that were unchanged. Kinome illustration reproduced courtesy of Cell Signaling 
Technology, Inc. (www.cellsignal.com). (B) The trend of kinase abundance changes for 
all kinases quantified. Dashed line, ± 1.5-fold change. (C) The kinome profile of MYL-R 
relative to MYL was derived from the kinases that were significantly changed after 
statistical analysis. The kinase abundance ratios and p-values from three independent 
experiments were combined and adjusted for multiple hypothesis testing and ratios with a 
Benjamini-Hochberg q-value < 0.2 were considered significant. Dashed lines, ± 1.5-fold 
change; error bars, SE (N=3).
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Figure 3.2. Validation of the MYL-R kinome profiles by immunoblotting.
(A and B) MYL and MYL-R cell lysates were analyzed by immunoblot with the antibod-
ies indicated. Representative data are shown. (A) ATM, BCR-Abl and c-Kit were 
decreased in MYL-R relative to MYL cells as predicted from the kinome profile above. 
(B, left panel) Both total and activated Lyn and PKCβ were increased in MYL-R cells as 
shown using antibodies to detect phosphorylation of the activation loop of Lyn (p-Y416) 
or the autophosphorylation site of PKCβ. (B, right panel) Total amounts of IKKα, MEK2 
and ERK1/2 were similar in MYL and MYL-R cells, however, phospho-specific antibod-
ies demonstrated these kinases were more active in MYL-R cells. (C) Kinases from MYL 
and MYL-R cell lysates were captured by MIBs pull-down and analyzed by immunoblot 
using antibodies directed against total protein. The relative amounts of kinases captured 
from each cell lysate correlated with the abundance ratios predicted by the MYL-R 
kinome profile. MIBs exposed to MYL-R cell lysate (C, left panel) captured less ASK1, 
Jak1, MLTK, Yes, GSK3α, CDK2 and dCK; and (C, right panel) captured more NEK9, 
IKKα, RIPK2, Lyn and ERK. See also, Figures S2 and S3.
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Figure 3.3. Lyn drives activation of MEK and increases activation of IKKα in 
MYL-R cells.
(A) MYL-R cells were treated for 1 hour with dasatinib, as indicated, and lysates were 
analyzed by immunoblot with the antibodies indicated. Lyn phosphorylation was detected 
by p-SFK (Y416). For densitometry, the band densities of p-SFK, p-MEK and p-IKKα 
were normalized against the β-actin loading control and were plotted relative to the 
DMSO treatment. Error bars, SE (N=3). (B) MYL-R cells were transduced with non-
targeting shRNA (shCtrl) or shRNA directed against Lyn (shLyn) and lysates were 
analyzed by immunoblot with the antibodies indicated. Lyn phosphorylation was detected 
by p-SFK (Y416) antibody. For densitometry, the band densities of p-IKKα and p-MEK 
were plotted relative to total IKKα and MEK protein expression. Error bars, SE (N=2).
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Figure 3.4. MYL-R cells exhibit increased NF-κB signaling.
(A) Total RNA was isolated from MYL and MYL-R cells and the expression of NF-κB 
target genes was evaluated by qRT-PCR. Error bars, SE (N=3). (B) MYL and MYL-R 
cells were treated for two hours with DMSO or the IKK inhibitor BAY 65-1942 (BAY, 10 
µM) and then analyzed by immunoblot using the antibodies indicated. The entire blot is 
shown in Figure S5. Error bars, SE (N=3). (C) MYL-R cells were treated for 12 hours 
with DMSO or BAY (10 µM) and total RNA was isolated and evaluated by qRT-PCR. 
Error bars, SE (N=3).
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Figure 3.5. Kinome response to targeted MEK and IKK inhibitor treatment.
(A) MYL-R cells were treated for 24 hours with AZD6244 (AZD, 5 µM), BAY 65-1942 
(BAY, 10 µM) or AZD (5 µM) plus BAY (10 µM), and kinases were isolated and quanti-
fied by MIB/MS in two independent experiments. The relative abundances 
(Drug/DMSO) of kinases in the MEK/ERK pathway are shown. Error bars, SE (N=2). 
(B) MYL-R cells were treated for 24 hours with AZD (5 µM), BAY(10 µM) or AZD (5 
µM) plus BAY (10 µM), and were analyzed by immunoblot using the antibodies indi-
cated. Data are representative of three separate experiments. (C) MYL-R cells were 
treated for 12 hours with AZD (5 µM), BAY (10 µM), AZD (5 µM) plus BAY (10 µM), 
or dasatinib (1 nM). Total RNA was isolated and the expression of IκBα and IL-6 were 
evaluated by qRT-PCR. Error bars, SE (N=2).
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Figure 6. Targeted inhibition of kinases detected by MIB/MS leads to induction of 
apoptosis.
(A) MYL-R cells were treated for 48 hours with AZD6244 (AZD, 5 µM), BAY 65-1942 
(BAY, 10 µM), AZD (5 µM) plus BAY (10 µM), or dasatinib (1 nM) and cell viability 
was assessed by MTS assay. Error bars, SE (N=3). (B) MYL-R cells were treated for 24 
hours with AZD (5 µM), BAY (10 µM), AZD (5 µM) plus BAY (10 µM), or dasatinib (1 
nM) and caspase 3/7 activity was assessed by fluorometric assay. Error bars, SE (N=2). 
(C) MYL-R cells were treated for 48 hours with AZD (5 µM), BAY (10 µM), AZD (5 
µM) plus BAY (10 µM), or dasatinib (1 nM) and cell lysates were analyzed by immunob-
lot using the antibodies indicated. Data are representative of two separate experiments.
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Figure 3.S1. MIB/MS analysis of kinases from MYL and MYL-R cells.
Kinases from MYL and MYL-R cells were analyzed by MIB/MS in three independent experiments. 
(A) Kinase abundance ratios (MYL-R/MYL) pooled from three experimental replicates using iTRAQ 
for relative quantification. Dashed lines, ± 1.5-fold change; error bars ± SE (N=3). (B) Comparison 
of kinase abundance ratios (MYL-R/MYL) obtained using iTRAQ and SILAC for relative quantifica-
tion. Kinases identified using both methods are shown. Dashed lines, ± 1.5-fold change; error bars
± SE (N=2). (C) The trend in kinase abundance ratio changes (MYL-R/MYL) using iTRAQ 
(triangles) compared to SILAC (squares) for relative quantification.
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Supplementary Figure S1B
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Figure 3.S2. Kinases bind to MIBs in an activity-dependent manner.
MYL and MYL-R cell lysates were treated with calf instestinal alkaline phosphatase and the 
amount of IKKα, Lyn and MEK captured by MIBs with and without phosphatase treatment was 
compared by immunoblot analysis using the antibodies indicated.
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Figure 3.S3. Phospho-IKKα is elevated in MYL-R cells.
Proteins from MYL and MYL-R cell lysates were separated by SDS-PAGE on a 6% poly-
acrylamide gel and the migrations of IKKα, IKKβ and phospho-IKK were compared by 
immunoblot analysis using antibodies against IKKα, IKKβ and phospho-IKKα/β.
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Figure 3.S4. MYL-R kinome response to dasatinib treatment.
MYL-R cells were treated for 1 hour with dasatinib (10 nM) or DMSO and changes to the 
kinome were analyzed by MIB/MS in a single experiment. Data is represented as changes in the 
kinase abundance ratios induced by dasatinib treatment. A total of 116 kinases were quantified. 
Dashed lines, ± 1.5-fold change; error bars ± SE.
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Figure 3.S5. IKK activity is blocked by the kinase inhibitor BAY 65-1942.
MYL and MYL-R cells were pre-treated for 2 hours with BAY 65-1942 (BAY, 10 μM) or DMSO 
and then stimulated with TNFα (10 ng/μL) for 5 minutes. The ability of BAY to block phosphory-
lation of p65 (S536) was analyzed by immunoblot using the antibodies indicated. This is the 
uncropped blot of that shown in Figure 4B.
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Figure 3.S6. MIB/MS analysis of MYL-R kinome response to targeted inhibition of MEK and IKK.
MYL-R cells were treated for 24 hours with DMSO, AZD6244 (AZD, 5 μM), BAY 65-1942 (BAY, 10 
μM), or AZD (5 μM) plus BAY (10 μM) and kinases were analyzed by MIB/MS in two independent 
experiments. The relative abundances (Drug/DMSO) of 111 quantified kinases are shown. Dashed
lines, ± 1.5-fold change; error bars, ± SE (N=2).
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Figure 3.S7. Figure S7. HL-60 AML cells differentiated with ATRA show increased 
phosphorylation of Lyn, IKKα and MEK.
HL-60 cells were treated for 96 hours with all-trans-retinoic acid (ATRA) (200 nM) or 
DMSO and cell lysates were analyzed by immunoblot with the antibodies indicated. Data 
are representative of three separate experiments.
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3.5 Experimental Procedures 
Cell culture and reagents 
MYL and MYL-R human CML cells were a generous gift from Dr. Hideo Tanaka 
(Dept. of Haematology and Oncology, Hiroshima University, Hiroshima, Japan) [101]. 
HL-60 cells were obtained from the UNC Lineberger Tissue Culture Facility (Chapel 
Hill, NC). Cells were cultured in RPMI 1640 medium (Thermo Scientific, Rockford, IL) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA) and 1% 
antibiotic/antimycotic (Invitrogen, Carlsbad, CA) and were maintained at 37°C in a 5% 
CO2 humidified atmosphere. For SILAC labeling, MYL and MYL-R cells were grown 
for at least six doublings in SILAC medium, as previously described [148]. For HL-60 
cell differentiation, cells were seeded at 1 x 105 cells per ml and then were returned to the 
incubator for 24 hours. The following day, cells were treated with 200 nM all-trans-
retinoic acid (ATRA) or DMSO, and then were returned to the incubator for an additional 
72 hours before harvesting and immunoblot analysis.Reagents were obtained from the 
following sources: imatinib and dasatinib were from LC Laboratories (Woburn, MA); 
BAY 65-1942 was from Theralogics, Inc. (Chapel Hill, NC); AZD6244 was synthesized 
as described previously [148]; TNFα was from Promega (Madison, WI); ATRA was from 
Sigma-Aldrich (St. Louis, MO). 
Multiplexed inhibitor bead affinity chromatography 
Isolation of kinases from MYL and MYL-R cell lysates was performed as 
described previously [114,148]. Briefly, cells were lysed on ice in MIB lysis buffer [50 
mM HEPES (pH 7.5), 0.5% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
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10 mM sodium fluoride, 2.5 mM sodium orthovanadate, 1X protease inhibitor cocktail 
(Roche), and 1% of phosphatase inhibitor cocktail 3 (Sigma)]. Cell lysates were sonicated 
3x10 seconds on ice and centrifuged at 10,000 x g for 10 min at 4 °C. The supernatant 
was collected and syringe-filtered through a 0.2 μm SFCA membrane. The filtered lysate 
(approximately 10-15 mg of protein per experiment) was brought to 1M NaCl and passed 
through a column of layered inhibitor-conjugated beads (MIBs) consisting of Sepharose-
conjugated Bisindoylmaleimide-X, Dasatinib, Purvalanol B, PP58 and VI16832  [113]. 
The MIBs were washed with 20 ml of high-salt buffer and 20 ml of low-salt buffer [50 
mM HEPES (pH 7.5), 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA, and 10 mM 
sodium fluoride, and 1M NaCl or 150 mM NaCl, respectively]. The columns were 
washed a final time with 1 ml 0.1% SDS before elution in 1 ml of 0.5% SDS (100 °C, 5 
min). Eluted kinases were reduced (dithiothreitol) and alkylated (iodoacetamide) prior to 
being concentrated with Amicon Ultra centrifugal filters (Millipore) and detergent was 
removed from the concentrated eluate by chloroform/methanol extraction. Protein pellets 
were resuspended in 50 mM HEPES (pH 8.0) and were digested for 24 hours with 
sequencing grade modified trypsin (Promega). Digested peptides were labeled with 
iTRAQ reagent (AB SCIEX, Framingham, MA) for 2 hours in the dark, according to the 
manufacturer’s instructions. Labeled peptides were cleaned using PepClean C18 spin 
columns (Thermo Scientific) before fractionation on a Tempo™ LC MALDI Spotting 
System (AB SCIEX) using a Chromolith® CapRod® RP-18e HR analytical column 
(Merck KGaA, Darmstadt, Germany). 
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MS analysis 
MS and MS/MS data were acquired on a MALDI TOF/TOF 5800 or 4800 (AB 
SCIEX). MS/MS spectra were searched against the Uniprot/Swiss-Prot database with 
ProteinPilot™ software version 3.0 (AB SCIEX) (Paragon algorithm 3.0.0.0, 113442) for 
peptide and protein identifications. Protein identifications were accepted with an Unused 
ProtScore > 1.3 (corresponding to > 95% confidence). Relative quantification of kinases 
bound to MIBs was determined with ProteinPilot™ using auto bias-correction and 
background correction. 
Statistical analysis of MIB/MS kinase quantification 
We performed three independent MIB/MS experiments to profile the kinomes of 
MYL and MYL-R cells and quantified a total of 153 unique kinases. For each kinase, we 
computed the pooled protein ratio and p-value across the three replicates as follows. Let 
yij denote the Log2 protein ratio for kinase i, i=1,…,153 in replicate j, j=1,2,3; and let wij 
denote the number of peptides used for calculation of the protein ratio for kinase i in 
replicate j. The pooled protein ratio for kinase i is defined as 2yi, where 
      3 13 1 j ijj ιjiji wywy . To avoid directional conflict, we convert the two-sided p-
values reported in ProteinPilot™ to one-sided p-values and denote it as pij. We applied 
Stouffer’s Z-score method to combine the p-values. Let zij = Φ-1(1-pij), where Φ is the 
standard Gaussian cumulative distribution function. Define the combined Z-score as 
     3 13 1 j ijj ijiji wZwZ . The combined two-sided p-value for kinase i is given as 
pi = 2(1-Φ(|Zi|)). For each replicate, we identified kinases that exhibit statistically 
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significant changes in expression based on Benjamini-Hochberg adjusted q-values at 
FDR of 0.2 to account for multiple comparisons. To profile the MYL-R kinome response 
to kinase inhibitor treatment we performed two independent MIB/MS experiments and 
three technical replicates of the second experiment. Kinase abundance ratios and p-values 
were pooled as described above. 
Immunoblot analysis 
Cells were collected and lysed using modified RIPA buffer (150 mM NaCl, 9.1 
mM Na2HPO4, 1.7 mM NaH2PO4, 1% NP-40, and 0.5% deoxycholic acid; adjusted to 
pH 7.4) supplemented with protease inhibitor cocktail (Roche Diagnostics, Mannheim, 
Germany), 1 mM sodium orthovanadate, and phosphatase inhibitor cocktail 3 (Sigma-
Aldrich). The lysate was centrifuged and the protein concentration was determined using 
Bradford reagent (Thermo Scientific). Gel samples were prepared by adding 20-40 µg 
protein lysate to Laemmli sample buffer [final concentration: 0.25 M Tris (pH 6.8), 10% 
glycerol, 5% β-mercaptoethanol, 0.001 g/ml Bromphenol blue] and the samples were 
separated by SDS-polyacrylamide gel electrophoresis and then transferred to a PVDF 
membrane (Millipore, Billerica, MA). Membranes were blocked with 5% non-fat dry 
milk or 5% bovine serum albumin in Tris-buffered saline supplemented with Tween-20 
(TBS-T) [10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.05% Tween-20] for 1 hour at 
room temperature. Membranes were incubated with primary antibodies for 1 hour at 
room temperature or overnight at 4 °C, followed by incubation with secondary antibodies 
for 1 hour at room temperature, and were then developed using Amersham ECL Western 
blotting detection reagents (GE Healthcare, Piscataway, NJ). Densitometry was 
84 
performed using ImageJ (NIH). Antibodies were from the following sources: BCR-Abl, 
p-SFK (Y416), p-IKKα/β, p-MEK1/2, MEK1/2, p-ERK1/2, ERK1/2, p-p65 (S536), p65, 
PARP, cleaved PARP, caspase 3 and cleaved caspase 3 were from Cell Signaling 
Technology (Danvers, MA); IKKα and IKKβ were from Millipore; β-actin, ATM, c-KIT, 
Lyn, p-PKCβ (T642), PKCβ and ERK2 were from Santa Cruz Biotechnology (Santa 
Cruz, CA); Anti-mouse and anti-rabbit IgG-HRP conjugated secondary antibodies were 
from Promega. Primary antibodies were diluted at 1:1,000 in 5% bovine serum albumin 
in TBS-T with the exception of Lyn (1:10,000). Secondary antibodies were diluted at 
1:10,000 or 1:15,000 in 5% dry, non-fat milk in TBS-T. 
MIBs pull-down assay 
To assess the phosphorylation-dependent binding of kinases to MIBs, MYL and 
MYL-R cells were harvested and lysed for 20 minutes on ice in buffer containing 50 mM 
Tris-HCl (pH 8.0), 0.5% NP-40, 150 mM NaCl, and 2X protease inhibitor cocktail 
(Roche). Lysate was cleared by centrifugation at 10,000 x g for 10 minutes at 4 °C and 
protein concentration was determined with Bradford reagent (Thermo Scientific). For 
each sample, 0.5 mg protein was adjusted to 1 mg/ml with lysis buffer and either treated 
with 100 units of calf intestinal alkaline phosphatase (New England Biolabs, Ipswich, 
MA) or, for un-treated samples, supplemented with phosphatase inhibitors. Samples were 
incubated at 30 °C for 30 minutes with mixing, then placed on ice. Kinases were isolated 
by mixing with 20 µL MIBs at 4 °C for 1 hour. MIBs were washed 3x with lysis buffer, 
then kinases were eluted with 40 µL 2X Laemmli sample buffer (100 °C, 5 minutes) and 
analyzed by immunoblotting (as above). 
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shRNA knock-down of Lyn 
pLKO.1 lentiviral vectors containing shRNA directed against Lyn or a non-
targeting shRNA were obtained from the UNC Vector Core. Lentiviral packaging vector 
psPAX2 (Addgene plasmid 12260) and envelope vector pMD2.G (Addgene plasmid 
12259) were obtained from Addgene, courtesy of Didier Trono (http://tronolab.epfl.ch/). 
Lentivirus production and MYL-R cell infection was done according to the protocol 
supplied by The RNAi Consortium 
(http://www.broadinstitute.org/rnai/public/resources/protocols). Transduced MYL-R cells 
were selected in media supplemented with puromycin (2 µg/mL) for one week and cells 
were harvested for analysis by immunoblotting. 
qRT-PCR 
RNA was isolated from cell lines using TRIzol™ reagent (Invitrogen) according 
to the manufacturer’s protocol. Reverse transcription was carried out on 5 μg RNA in a 
20 µL reaction using SuperScriptII reverse transcriptase (Invitrogen) and random 
primers, according to the manufacturer’s protocol. The cDNA was analyzed by real-time 
qPCR using inventoried TaqMan™ Gene Expression Assays (AB Sciex) on an Applied 
Biosystems 7500 Fast Real-Time PCR System. 
Caspase 3/7 activity assay 
MYL-R cells (1 x 106) were incubated with kinase inhibitors for 24 hr, lysed on 
ice for 20 minutes with 100 µL lysis buffer [50 mM HEPES (pH 7.4), 5 mM CHAPS and 
5 mM DTT], then centrifuged at 10,000 x g for 10 min at 4 °C. In a 96-well plate, 10 µL 
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of supernatant was added to 200 µL of assay buffer [20 mM HEPES (pH 7.4), 0.1% 
CHAPS, 2 mM EDTA, 5 mM DTT and 15 µM Ac-DEVD-AMC caspase 3/7 substrate 
(Sigma-Aldrich)] and the plate was incubated in the dark for 2 hours at room 
temperature. The fluorescence of liberated AMC (7-amido-4-methylcoumarin) was 
measured using a FLUOstar Galaxy plate reader (BMG Labtech, Cary, NC) with a 360-
nm excitation filter and a 460-nm emission filter. 
Cell viability assay 
Cell viability was determined by seeding MYL-R cells on a 96-well plate at 4 x 
104 cells per well in 100 µL RPMI growth medium supplemented with kinase inhibitors. 
Growth media and kinase inhibitors were replenished at 24 hr, and at 48 hr. 20 µL of 
MTS assay reagent (CellTiter 96 AQueous One Solution Cell Proliferation Assay™, 
Promega) was added to each well. The plate was returned to the incubator for 
approximately 1 hour and the absorbance at 490 nm was recorded. 
 
 
 
 CHAPTER IV 
SUMMARY 
4.1 Diverse roles for IKKα in cancer signaling 
Protein kinases are critical mediators of cellular signaling, frequently 
demonstrating the capacity for oncogenic signaling if they are dysregulated. 
One such kinase, IKKα, is often involved in oncogenic initiation and progression through 
its role in activating NF-κB [15]. However, depending on the context this same kinase 
may function as a tumor suppressor [58]. This concept has been demonstrated here 
through: 1) studies exploring the functional relationship between IKKα and the nuclear 
hormone receptor AR (Chapter 2), and 2) through kinome profiling of a drug-resistant 
CML cell line that identified IKKα as one of the essential mediators of drug resistance. 
4.2 IKKα attenuates androgen receptor activity in prostate cancer 
Androgen receptor regulation is a complex process where transcriptional activity 
is a function of AR interdomain conformation, ligand binding affinity, dimerization, 
protein stability, and subcellular localization. Each of these is in turn influenced by 
interacting proteins and by posttranslational modifications. In a recent update from the 
Androgen Receptor Gene Mutations Database, AR was reported to interact with 311 
different proteins, a majority of which are transcriptional coactivators and corepressors 
[189]. The AR also has 23 confirmed sites of posttranslational modification including 
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phosphorylation, methylation, acetylation, SUMOylation and ubiquitination [67]. 
Nevertheless, given the reports of IKKα as an essential promoter of ERα-mediated gene 
transcription [51], we explored the possibility that IKKα might play an analogous role in 
promoting androgen receptor (AR) activity.  
In Chapter 2, I defined a previously uncharacterized role for IKKα in regulating 
AR activity. These studies demonstrated that IKKα physically interacted with AR and 
attenuated its transcriptional activity. The interaction of IKKα with AR was observed in 
three different prostate cancer cell lines as well as in HEK 293T cells, indicating that the 
regulatory role of IKKα may extend to other cell types where AR functions [136–138]. 
Transient IKKα overexpression inhibited AR transcriptional activity measured by 
qRT-PCR with a concomitant decrease in AR protein levels. And conversely, genetic 
silencing or pharmacological inhibition of IKKα resulted in increased AR activity with a 
concomitant increase in AR protein levels. The observation that IKKα inhibition led to 
increased AR protein expression was recently corroborated by work with mice in our lab 
showing that simultaneous knockout of PTEN and IKKα led to increased expression of 
prostate AR (H. Dan, personal communication). 
As a nuclear hormone receptor, the subcellular localization of AR is crucial for its 
activation. IKKα and AR co-localized to the nucleus within 15 minutes of stimulation of 
cells with DHT, however nuclear IKKα levels declined within 60 minutes as AR levels 
remained steady. This may suggest a mechanism of regulation where IKKα translocates 
to the nucleus with AR and plays a role in the reordering of AR dimers as they bind DNA 
and recruit coregulators [139]. Another possibility is that IKKα is induced to translocate 
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to the nucleus independent of AR as one of the non-genomic aspects of androgen 
signaling [140]. 
Both genetic and pharmacological inhibition of IKKα resulted in increased AR 
nuclear accumulation. Short term pharmacological inhibition (1 hr treatment) precludes 
regulation of AR by IKKα via changes in gene transcription, a possible scenario whereby 
IKKα would inhibit an AR feed-forward loop resulting in loss of its transcription. These 
results suggest a more direct mechanism of AR regulation by IKKα. 
In vitro kinase assays resulted in robust phosphorylation of AR by IKKα and mass 
spectrometry mapped the phosphorylation to strong IKK phosphorylation motif at Ser29. 
Metabolic labeling of cells with 32P-orthophosphate resulted in immunoprecipitation of 
an AR species detected by autoradiography when IKKα was overexpressed, indicating 
that IKKα can phosphorylate AR in vivo. Phosphorylation of AR by IKKα was confirmed 
with the use of a phospho-motif antibody that detects p-Ser29. AR Ser29 phosphorylation 
was detected in cells co-transfected with IKKα and AR wild-type, but this signal was lost 
with the AR S29A mutant. 
Ser29 flanks the FXXLF domain that is essential for interaction between the N- 
and C-terminal domains. This hydrophobic motif competes with AR coregulators for 
binding to a hydrophobic cleft that is formed on the AR ligand binding domain (LBD) 
when agonist is bound and in some circumstances can lead to diminished AR 
transcriptional activity as the AR LBD AF-2 region is sequestered from coactivators. The 
FXXLF motif maintains interaction with the AF-2 via a charge clamp, mediated in part 
by AR Lys720 extending hydrogen bonds to Ser29 [141,142]. It is thus intriguing to 
speculate that the mechanism of IKKα regulation of AR lies in phosporylation of Ser29, 
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which would increase an existing negative charge in the area surrounding Ser29, inducing 
a stronger interaction between Ser29 and Lys720 [143] thereby inhibiting AR activity by 
preventing interaction with coactivators. 
Further work needs to be done to validate AR Ser29 as a bona fide IKKα 
substrate. Despite multiple attempts, I was unable to identify any AR phosphorylation 
sites in vivo. AR is constitutively phosphorylated, and I was able to show in vivo 
incorporation of 32P into AR by immunoprecipitation and SDS-PAGE, so failure to map 
in vivo phosphorylation sites points to technical difficulties that can be overcome. 
Finally, phosphorylation of AR at Ser29 likely alters its association with 
cofactors. I attempted to co-immunoprecipitate a few AR coregulators without success, 
but AR has some 311 interacting proteins. Important data could be gleaned from a 
relatively straightforward experiment where AR wild-type and S29A are transiently 
expressed, AR is immunoprecipitated and interacting proteins are identified by mass 
spectrometry. 
4.3 Profiling of kinome adaptations in CML 
Owing to their position as regulators of cellular signaling, protein kinases are 
regulated through multiple mechanisms of feedback inhibition and cross-talk that form 
nodes through which kinase networks are essentially interrelated [190]. Perturbations in 
these relationships lead not only to kinase dysregulation but to changes in the kinome as a 
whole. 
Chapter 3 of this dissertation discussed the application of multiplexed kinase-
inhibitor-conjugated beads coupled with quantitative mass spectrometry (MIB/MS) to 
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investigate kinome adaptations in a cell line model of Lyn-driven, imatinib-resistant 
CML (MYL-R) compared to its imatinib-sensitive counterpart (MYL) [101]. We 
identified multiple changes associated with drug-resistance in MYL-R cells, including 
activation of IKKα and MEK downstream of Lyn signaling. Furthermore, MIB/MS 
analysis of the kinome response to targeted kinase inhibition identified a compensatory 
increase in MEK/ERK signaling when IKKα was inhibited alone. Combined targeted 
inhibition of IKKα and MEK, as guided by MIB/MS, overcame MYL-R drug resistance 
and synergistically inhibited cell viability, leading to apoptosis. 
Our ultimate aim was to develop and apply this technology to obtain insight into 
the molecular adaptations of drug-resistant cells with the goal of using this information to 
rationally target kinases contributing to imatinib resistance. Using multiple, structurally 
distinct kinase inhibitors, this MALDI-TOF/TOF MS based technology provides a high 
throughput, quantitative approach to interrogate the kinome as described earlier [148]. 
Importantly, these studies demonstrated that kinase binding to MIBs was a function of 
both activity and expression, hence MIBs can be used to profile the “activation state” of 
the kinome. Our studies confirm this and show the utility of the MIB/MS approach to 
study kinome adaptations in drug resistant cells and have identified significant 
quantitative differences in the kinomes of MYL and MYL-R cells. 
In three independent experiments our MIB/MS approach identified and quantified 
a total of 153 kinases, nearly 50% of the estimated expressed kinome [148,180]. For the 
purpose of establishing a MYL-R kinome profile, the significance of these quantifications 
was established through statistical analysis and only kinase abundance ratios with 
Benjamini-Hochberg-adjusted p-values < 0.2 were considered to be significantly 
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different. This resulted in identification of 35 kinases that constitute the MYL-R kinome 
profile. Changes in kinase abundance were confirmed by immunoblotting in all 19 of the 
kinases investigated, confirming the sensitivity and accuracy of MIB/MS. 
Lyn is a SFK with an established role in promoting the survival of imatinib-
resistant CML cells from patients and cell lines such as MYL-R independently of BCR-
ABL mutations [95,100–102,104,176–178]. MIB/MS confirmed the increased expression 
and activation of Lyn in MYL-R cells as reported initially by Ito [101] and others [179]. 
Using MIB/MS we also detected a substantial number of kinases not previously reported 
to be increased or decreased in imatinib-resistant cells. 
Further evidence for Lyn as a regulator of the MEK/ERK pathway was supported 
by our shRNA data and is consistent with earlier observations demonstrating Lyn as an 
activator of MEK [158]. By contrast, the mechanism by which Lyn regulates IKKα or 
other kinases in MYL-R cells (Nek9, PRPK etc.) remains to be elucidated. We also 
detected a significant increase in PKCβ activity, both by MIB/MS and by 
immunoblotting. PKCβ has been shown to regulate anti-apoptotic responses in myeloid 
leukemias [181], however inhibition of PKCβ with bryostatin did not affect the viability 
of MYL-R cells (unpublished observations).  Interestingly, a recent proteomics study 
profiling kinase expression in drug-refractory head and neck squamous cell carcinoma 
identified a number of the same kinases (Lyn, MEK, NEK9) as we did in MYL-R cells, 
suggesting that these may represent a drug resistant kinome profile [182]. 
The MYL-R kinome profile revealed up-regulation of multiple kinases involved 
in cell growth, anti-apoptosis and stress signaling. This included kinases such as MEK2 
and ERK2 (MEK/ERK pathway), IKKα (NF-κB pathway) and others NEK9 (mitotic 
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regulation), PRPK (TP53-activating kinase), AAKG1 (AMP-activated protein kinase), 
RIPK2 (innate immune response) and PRKDC (DNA-dependent protein kinase/DNA 
damage response). Interestingly, the decreased binding of JNK (MK08) and kinase 
regulators of JNK [ASK1 (M3K5), HPK1 (M4K1), HGK (M4K4), ZAK (MLTK)], 
indicate a decrease in this pro-apoptotic regulatory pathway in MYL-R cells [183,184]. 
Down-regulation of these kinases could potentially contribute to the anti-apoptotic 
properties of MYL-R cells. Decreased NDKM (nucleoside diphosphate kinase) or DCK 
(deoxycytidine kinase) may also contribute to the reduced sensitivity of MYL-R cells to 
nucleoside analogs (gemicitabine, Ara-C) that we observed previously (unpublished 
observations).  
NF-κB plays a key role in regulating anti-apoptotic responses to chemotherapy 
[15]. Because we detected increased IKKα and NF-κB signaling in MYL-R cells we 
examined the specific effects of targeting this pathway. BAY 65-1942 is a selective 
inhibitor of IKK (alpha and beta isoforms) and an inhibitor of NF-κB responses 
[130,187,188]. While BAY 65-1942 effectively blocked IκBα expression as expected, it 
stimulated a surprising increase in IL-6 expression in MYL-R cells that correlated with 
increased ERK phosphorylation. MIBs analysis of MYL-R cells treated with BAY 65-
1942 confirmed the activation of the MEK/ERK pathway and an increase in B-Raf, ERK 
(MK01) and RSK (KS6A1) binding was detected. Since our results suggested that BAY 
65-1942 triggered a compensatory activation of the MEK/ERK pathway, we examined 
the effects of co-targeting these pathways. The MIB/MS analysis of the response to BAY 
65-1942 and the MEK inhibitor AZD6244 was complex, with many kinases significantly 
lowered, including B-Raf, MEK (MAP2K1), and RSK (KS6A1) after combination 
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treatment. Importantly, the combination of these inhibitors not only prevented the BAY 
65-1942-stimulated increase in IL-6 and phospho-ERK, but synergistically reduced cell 
viability and increased apoptosis as determined by PARP cleavage and caspase 3/7 
activation. 
The MIB/MS kinome profiling studies conducted here yielded comprehensive (an 
estimated 50% of the expressed kinome) data on the kinome adaptations associated with 
drug-resistance in MYL-R cells. Lyn kinase was confirmed to be upregulated and 
additional activated kinases were identified. Moreover, MIB/MS analysis of cells treated 
with single kinase inhibitors illustrated the need for combined kinase inhibitor treatment. 
The MYL-R kinome response profiles to MEK and IKK inhibition confirmed the 
propensity of the kinome to dynamically reprogram. However, these kinome response 
profiles also provided an experimental rationale for co-targeting the IKK and MEK/ERK 
pathways and provided insight into why combined inhibition was more effective than 
MEK or IKK inhibition alone. 
MIB/MS kinome profiling is directly applicable to the study of other mechanisms 
of drug resistance. Our current work is focused on kinome profiling of AML cell lines 
and samples contributed from AML patients. A recent analysis has identified candidate 
kinases driving the survival of a FLT3 inhibitor-resistant cell line, and future experiments 
will assess the ability of combined targeted therapy to overcome this resistance. These 
advances affirm the potential of MIB/MS kinome profiling to identify dysregulated 
kinases in a particular disease setting, or even on an individualized basis, with the hope of 
eventually guiding the use of targeted therapy in a clinical setting. 
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